



11.04.2018

12:00 - 13:00	Industry Satellite Symposium 1	Room A
13:00 - 13:30	Welcome reception	Hall 1
13:30 - 13:45	Opening and welcome	Room B
13:45 - 14:15	HHH Award Keynote Lecture	Room B
13:45 - 14:15	HHH Award Keynote lecture	
14:30 - 16:00	First line for oncogene addicted lung cancer	Room B
14:30 - 14:50	Is PFS still a relevant endpoint for first-line TKIs? <u>S. Ramalingam</u> , Atlanta, US	
14:50 - 15:10	First vs second vs third generation EGFR TKI <u>J. Wolf</u> , Köln, DE	
15:10 - 15:30	Key factors that determine the selection of first-line ALK inhibitors <u>F. Blackhall</u> , Manchester, GB	
15:30 - 15:50	The role of first-line combination therapy for oncogene addicted lung cancer <u>T. Seto</u> , Fukuoka, Fukuoka/JP	
15:50 - 16:00	Q&A	



14:30 - 16:00	Combined treatment stage III	Room A
14:30 - 14:50	When concurrent chemo-radiotherapy is not the preferred choice <u>P. Fournel</u> , St. Priest En Jarez, FR	
14:50 - 15:10	Are current NTCP models useful for predicting radiation-induced toxicity? <u>D. De Ruyscher</u> , Maastricht, NL	
15:10 - 15:30	Surgical salvage of recurrences following CT-RT: Indications and outcomes <u>C. Dickhoff</u> , Amsterdam, NL	
15:30 - 15:50	Immunotherapy in the stage III paradigm: Rationale and clinical data <u>S. Peters</u> , Lausanne, CH	
15:50 - 16:00	Q&A	
16:00 - 16:30	Coffee break	Hall 1
16:30 - 18:00	First line for non-oncogene addicted lung cancer	Room B
16:30 - 16:50	First-line chemotherapy in NSCLC: Where do we stand? <u>R.A. Stahel</u> , Zürich, CH	
16:50 - 17:10	Immunotherapy in the first-line setting: What have we achieved? <u>M. Reck</u> , Grosshansdorf, DE	
17:10 - 17:30	First-line therapy in PS2 and elderly patients: Any new signals? <u>E. Quoix</u> , Strasbourg, CEDEX/FR	
17:30 - 17:50	First-line therapy: What might we expect for the future? <u>G. Scagliotti</u> , Orbassano, TO/IT	
17:50 - 18:00	Q&A	



16:30 - 18:00	Early stage NSCLC: Where do we stand in 2018?	Room A
16:30 - 16:50	Guidelines for surgery in ground glass opacities <u>K. Suzuki</u> , Tokyo, JP	
16:50 - 17:10	Pathology and biomarkers in resected NSCLC <u>E. Brambilla</u> , La Tronche, CEDEX 9/FR	
17:10 - 17:30	Neoadjuvant immunotherapy in early-stage NSCLC <u>P. Forde</u> , Baltimore, US	
17:30 - 17:50	Stereotactic radiotherapy for early stage NSCLC <u>S. Siva</u> , Melbourne, AU	
17:50 - 18:00	Q&A	
18:30 - 20:00	Industry Satellite Symposium 2	Room A

12.04.2018

07:45 - 09:00	Poster Discussion 1	Room A
07:45 - 07:45	134PD - Primary PFS and safety analyses of a randomized Phase III study of carboplatin + paclitaxel +/- bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) <u>M. Reck</u> ¹ , <u>M. Socinski</u> ² , <u>F. Cappuzzo</u> ³ , <u>F. Orlandi</u> ⁴ , <u>D. Stroyakovskiy</u> ⁵ , <u>N. Nogami</u> ⁶ , <u>D. Rodríguez-Abreu</u> ⁷ , <u>D. Moro-Sibilot</u> ⁸ , <u>C. Thomas</u> ⁹ , <u>F. Barlesi</u> ¹⁰ ; ¹ Grosshansdorf, DE, ² Orlando, US, ³ Ravenna, IT, ⁴ Santiago, CL, ⁵ Moscow, RU, ⁶ Matsuyama, JP, ⁷ Las Palmas, ES, ⁸ Grenoble, FR, ⁹ Scarborough, ME/US, ¹⁰ Marseille, CEDEX 20/FR	
07:45 - 07:45	135PD - A Phase 1b Study of Necitumumab in Combination with Abemaciclib in Patients with Stage IV Non-Small Cell Lung Cancer <u>B. Besse</u> ¹ , <u>F. Barlesi</u> ² , <u>I. Demedts</u> ³ , <u>J. Fuentes Pradera</u> ⁴ , <u>A. Renault</u> ⁵ , <u>G. Robinet</u> ⁶ , <u>B. Fridmodt-Moller</u> ⁷ , <u>M. Gil</u> ⁸ , <u>J. Vansteenkiste</u> ⁹ ; ¹ Villejuif, CEDEX/FR, ² Marseille, CEDEX 20/FR, ³ Roeselare, BE, ⁴ Sevilla, ES, ⁵ Pau, FR, ⁶ Brest, FR, ⁷ Copenhagen, DK, ⁸ Warsaw, PL, ⁹ Leuven, BE	
07:45 - 07:45	136PD - 3-year survival and duration of response in randomized Phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR) <u>J. Mazieres</u> ¹ , <u>K. Park</u> ² , <u>C. Lewanski</u> ³ , <u>S. Gadgeel</u> ⁴ , <u>L. Fehrenbacher</u> ⁵ , <u>A. Rittmeyer</u> ⁶ , <u>J. Han</u> ⁷ , <u>A. Artal-Cortes</u> ⁸ , <u>F. Braiteh</u> ⁹ , <u>M. Gandhi</u> ¹⁰ ; ¹ Toulouse, FR, ² Seoul, KR, ³ London, GB, ⁴ Ann Arbor, MI/US, ⁵ Vallejo, CA/US, ⁶ Immenhausen, DE, ⁷ Goyang, KR, ⁸ Zaragoza, ES, ⁹ Las Vegas, NV/US, ¹⁰ South San Francisco, CA/US	
07:45 - 07:45	137PD - Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)	



O. Juan, J. Méndez, B. Domingo-Arrué, D. Lorente Estelles, C. Escoín, C. Salvador Coloma, E. Navarro, M. Melian Sosa, N. Mancheño, J. Gomez Codina; Valencia, ES

- 07:45 - 07:45 138PD - Patient-reported outcomes (PROs) in ALEX: a phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)
M. Perol¹, S. Peters², N. Pavlakis³, E. Levchenko⁴, M. Platania⁵, J. Oliveira⁶, S. Novello⁷, T. Karagiannis⁸, A. Zeaiter⁹, R. Dziadziuszko¹⁰; ¹Lyon, FR, ²Lausanne, CH, ³St Leonards, NSW/AU, ⁴St-Petersburg, RU, ⁵Milano, IT, ⁶Porto, PT, ⁷Orbassano, IT, ⁸San Francisco, US, ⁹Basel, CH, ¹⁰Gdansk, PL
- 07:45 - 07:45 139PD - Patient-reported outcomes from FLAURA: osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC)
N. Leigh¹, N. Karaseva², K. Nakagawa³, B. Cho⁴, J. Gray⁵, T. Hovey⁶, A. Walding⁶, A. Rydén⁷, S. Novello⁸; ¹Toronto, CA, ²Saint Petersburg, RU, ³Izumi, JP, ⁴Seoul, KR, ⁵Tampa, US, ⁶Cambridge, GB, ⁷MÖlndal, SE, ⁸Orbassano, IT
- 07:45 - 07:45 140PD - Complex Epidermal Growth Factor Receptor (EGFR) Mutations and Responses to Tyrosine Kinase Inhibitors (TKIs) in Advanced Lung Adenocarcinomas
B. Zhang, S. Wang, J. Qian, W. Yang, F. Qian, J. Lu, Y. Zhang, R. Qiao, B. Han; Shanghai, CN
- 07:45 - 07:45 141PD - A Prospective Study of Molecular Testing Status in the EGFR mutation positive NSCLC patients with disease progression during EGFR TKI treatment (REMEDY study)
K. Kanai¹, N. Yamamoto¹, N. Nogami², S. Atagi³, H. Saka⁴, N. Tashiro⁵, T. Seto⁶; ¹Wakayama, JP, ²Matsuyama, JP, ³Sakai, Osaka/Jp, ⁴Nagoya, JP, ⁵Osaka, JP, ⁶Fukuoka, Fukuoka/Jp
- 07:45 - 07:45 142PD - Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma with Brain Metastases
L. Shi, Z. Liu, J. Tang, H. Wu, L. Guo, M. Li, L. Tong, W. Wu, H. Tao, W. Wu; Beijing, CN
- 07:45 - 07:45 143PD - Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7
J.C. Yang¹, Y. Wu², V. Hirsh³, K. O'byrne⁴, N. Yamamoto⁵, S. Popat⁶, A. Tamiya⁷, A. Märten⁸, M. Schuler⁹; ¹Taipei, TW, ²Guangzhou, CN, ³Montreal, QC/CA, ⁴Brisbane, QLD/AU, ⁵Shizuoka, JP, ⁶London, GB, ⁷Osaka, JP, ⁸Ingelheim Am Rhein, DE, ⁹Essen, DE
- 07:45 - 07:45 144PD - Leptomeningeal metastases in EGFR-mutated non-small cell lung carcinoma: management after tyrosine kinase inhibitors
R. Flippot¹, E. Auclin¹, P. Biondani², J. Adam³, D. Planchard³, C. Caramella³, C. Le Pechoux⁴, L. Lacroix³, L. Mezquita³, B. Besse⁴; ¹Paris, FR, ²Milan, IT, ³Villejuif, FR, ⁴Villejuif, CEDEX/FR



08:00 - 08:50 Management of CT detected small nodules Room A

08:00 - 08:15 Controls and timeline in the presence (or not) of small pulmonary nodules detected during lung cancer screening

M. Ruparel, London, GB

08:15 - 08:30 Surgical management of small pulmonary nodules detected during lung cancer screening

A. Brunelli, Leeds, GB

08:30 - 08:50 Discussion

08:00 - 08:50 Management of oligometastatic disease Room W

08:00 - 08:15 Evolving role of radiation therapy in oligometastatic disease: Beyond brain and lung stereotactic radiotherapy

M. Guckenberger, Zürich, CH

08:15 - 08:30 Is it possible to improve patients outcome in oligometastatic NSCLC with local therapy?

R. Rami-Porta, Terrassa, Barcelona/ES

08:30 - 08:50 Discussion

09:00 - 10:30 Second line in non-oncogene addiction Room B

09:00 - 09:20 Chemotherapy combined with antiangiogenics: Which patients and when?

M. Garassino, Milan, IT

09:20 - 09:40 Immunotherapy: Which patients and when?

E. Garon, Santa Monica, CA/US

09:40 - 10:00 Hyperprogressive disease in second-line

B. Besse, Villejuif, CEDEX/FR

10:00 - 10:20 New promising strategies in second-line

10:20 - 10:30 Q&A



09:00 - 10:30	Young Oncologist session	Room C
09:00 - 09:15	Management of oligometastatic NSCLC with driver mutations <u>R. Califano</u> , Manchester, GB	
09:15 - 09:30	The curious case of the EGFR mutations trend in a NSCLC oligometastatic patient <u>F. Napolitano</u> , Napoli, IT	
09:30 - 09:45	Q&A/Discussion	
09:45 - 10:00	How to prepare a relevant clinically-based project in lung cancer <u>L. Paz-Ares</u> , Madrid, ES	
10:00 - 10:15	The importance of mentorship in the European environment <u>R.A. Stahel</u> , Zürich, CH	
10:15 - 10:30	Q&A/Discussion	
09:15 - 10:15	Uncommon driver alterations: Should we use off-label targeted agents?	Room A
09:15 - 09:25	Introduction and first vote	
09:25 - 09:45	Follow guidelines of non oncogene addicted NSCLC <u>F. Ciardiello</u> , Napoli, IT	
09:45 - 10:05	Give an off-label prescription based on the best knowledge <u>J. Mazieres</u> , Toulouse, FR	
10:05 - 10:15	Second vote and conclusions	
10:30 - 11:00	Coffee break	Hall 1



11:00 - 12:30 Developments in pharmacology for systemic therapy Room A

- 11:00 - 11:20 Pharmacokinetics and interaction for TKI treatment
S. Popat, London, GB
- 11:20 - 11:40 Dosing and scheduling of monoclonal antibodies
T. Yap, Houston, Surrey/US
- 11:40 - 12:00 Target treatment combinations: Rationale and evidence
D. Carbone, Columbus, OH/US
- 12:00 - 12:20 Interactions of immunotherapy with other therapies
S. Champiat, Villejuif, CEDEX/FR
- 12:20 - 12:30 Q&A/Panel discussion

11:00 - 12:30 State of the art of PD-L1 testing Room C

- 11:00 - 11:20 Choosing PD-L1 assay(s) for a pathology lab
K. Kerr, Aberdeen, GB
- 11:20 - 11:40 Establishing PD-L1 laboratory developed assay
S. Lantuejoul, La Tronche, CEDEX 9/FR
- 11:40 - 12:00 Automation in PD-L1 analysis
D. Rimm, New Haven, CT/US
- 12:00 - 12:20 Clinical reporting of PD-L1 test results
J.R. Gosney, Liverpool, GB
- 12:20 - 12:30 Q&A/Panel discussion



11:00 - 12:30 Advances in surgery Room W

- 11:00 - 11:20 The relevance of pre-resection transcervical lymphadenectomy in lung cancer
S. Call, Terrassa, ES
- 11:20 - 11:40 Present indications of wedge resections and segmentectomy in lung cancer: Any clues from the ongoing clinical trials?
H. Asamura, Tokyo, JP
- 11:40 - 12:00 Why it is important to keep the Residual Tumour (R) descriptor after pTNM: Results from the analyses of the IASLC database
J. Edwards, Sheffield, GB
- 12:00 - 12:20 Resection of progressive disease after SBRT
P. Van Schil, Edegem, BE
- 12:20 - 12:30 Q&A/Panel discussion

11:00 - 12:30 Advances in radiation Room X

- 11:00 - 11:20 Stereotactic radiotherapy (SBRT/SABR): State of the art in 2018
F. Mornex, Pierre Bénite, CEDEX/FR
- 11:20 - 11:40 MRI guided radiation therapy
S. Senan, Amsterdam, NL
- 11:40 - 12:00 Role of proton therapy for lung cancer
J. Bradley, St. Louis, US
- 12:00 - 12:20 Role of carbon therapy for lung cancer
Y. Nakayama, Yokohama, JP
- 12:20 - 12:30 Q&A/Panel discussion

12:30 - 13:00 Poster Display session Hall 1

- 12:30 - 12:30 4P - Assessment of PD-L1 expression by immunohistochemistry in histological and cytological non-small cell lung carcinoma (NSCLC) in the era of immunotherapy: a national Irish study
A. Fabre, K. Breen, J. McCormack; Dublin, IE
- 12:30 - 12:30 5P - Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of non-small cell lung cancer
Y. Saito, S. Horiuchi, H. Morooka, T. Ibi, N. Takahashi, T. Ikeya, E. Hoshi, S. Shimizu; Saitama, JP



- 12:30 - 12:30 6P - Mechanisms of regulating PD-L1 expression in Non-Small Cell Lung Cancer during EMT process
F. Li, L. Liang; Beijing, CN
- 12:30 - 12:30 7P - The Regulation of FOXP3 Expression by GLI-1 in non-small Cell Lung Cancer Cells and its Influence on Lung Cancer Cell Stemness
H. Qi¹, H. Jia², G. Chen²; ¹Hong Kong, HK, ²Hong Kong, CN
- 12:30 - 12:30 8P - Noncanonical Wnt11, a tumor suppressive gene by antagonizing canonical Wnt signaling, represents a putative molecularly therapeutic target in lung cancer.
X. Wang, Shatin, HK
- 12:30 - 12:30 9P - Mesenchymal stem cells' microvesicles from primary and metastatic NSCLC niches differentially modulate lung cancer cells
O. Attar-Schneider, L. Drucker, M. Gottfried; Kfar Saba, IL
- 12:30 - 12:30 10P - The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact
R. Shemesh¹, Y. Gorzalczyan¹, N. Peled², R. Sagi-Eisenberg¹; ¹Tel Aviv, IL, ²Beer Sheva, IL
- 12:30 - 12:30 11P - Glycolysis enzyme screenings identify non-glycolytic function of aldolase A that interacts and alters F-actin dynamics to promote lung cancer metastasis
Y. Chang¹, M. Hsiao²; ¹Taipei City, TW, ²Taipei, TW
- 12:30 - 12:30 12P - Cigarette smoke promotes proliferation of non-small cell lung cancer (NSCLC) via enhancing glucose uptake and glycolysis.
I. Hsieh, F. Cheng, C. Tu, C. Chen, T. Hsia, B. Wang, Y. Yeh, W. Huang; Taichung, TW
- 12:30 - 12:30 13P - The identification of binding targets for pro-metastatic protein NIFK in lung cancer
T.C. Lin, Taoyuan, TW
- 12:30 - 12:30 14P - MMP-2 1306 C/T Promoter Polymorphism and Smoking: a Possible Role as Risk Factors in Lung Cancer
A. Daniele, D. Rosa, V. Lapadula, I. Abbate, D. Galetta, E. Montagna, A. Catino; Bari, IT
- 12:30 - 12:30 15P - Comprehensive profiling of lincRNAs in lung adenocarcinoma of never smokers reveals their important roles in cancer development and prognosis
Y. Li¹, X. Zhang¹, Z. Sun²; ¹Zhengzhou, CN, ²Rochester, MN/US
- 12:30 - 12:30 16P - Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression
C. Qinnan, W. Zhaoxia; Nanjing, CN
- 12:30 - 12:30 17P - Long non-coding RNA SNHG20 promotes non-small cell lung cancer cell progression by silencing of P21 expression
C. Zhenyao, C. Xin, W. Zhaoxia; Nanjing, CN



- 12:30 - 12:30 18P - The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer
W. Chenchen, W. Zhaoxia; Nanjing, CN
- 12:30 - 12:30 19P - Single Sample Predictor of Non-Small Cell Lung Cancer Histology Based on Gene Expression Analysis of Archival Tissue
A. Karlsson¹, H. Cirenajwis¹, K. Ericson-Lindqvist¹, C. Reuterswärd¹, M. Jönsson¹, A. Patthey², A. Behndig², M. Johansson², M. Planck¹, J. Staaf¹; ¹Lund, SE, ²Umea, SE
- 12:30 - 12:30 20P - ArgSS1 Expression in Squamous Cell Carcinoma of the Lung
E. Cathcart-Rake¹, A. Roden¹, A. Mansfield²; ¹Rochester, US, ²Rochester, MN/US
- 12:30 - 12:30 21P - Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen.
M. Van Seijen¹, L. Brcic², A. Navarro³, I. Sansano⁴, M. Béndek⁵, B. Witte¹, I. Brcic², R. Kammler⁶, R.A. Stahel⁷, E. Thunnissen¹; ¹Amsterdam, NL, ²Graz, AT, ³Valencia, ES, ⁴Barcelona, ES, ⁵Stockholm, SE, ⁶Bern, CH, ⁷Zürich, CH
- 12:30 - 12:30 22P - Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma
V. Tischler¹, M. Ihle¹, A. Stenzinger², W. Weichert³, W. Jochum⁴, R. Büttner⁵, J. Wolf¹, M. Peifer¹, R. Thomas¹; ¹Köln, DE, ²Heidelberg, DE, ³München, DE, ⁴St. Gallen, CH, ⁵Cologne, DE
- 12:30 - 12:30 23P - Genomic profiling of gene aberrations in 323 Chinese NSCLC patients
Y. Liu¹, C. Xu², W. Wang³, Z. Song³, Y. Zhu⁴, Y. Guan⁵, R. Chen⁵, G. Chen³, T. Lv⁶, Y. Song⁶; ¹Shijiazhuang, CN, ²Fuzhou, CN, ³Hangzhou, CN, ⁴Jiaying, CN, ⁵Beijing, CN, ⁶Nanjing, CN
- 12:30 - 12:30 24P - Proviral Integration site for Moloney murine leukemia virus-1 (PIM-1) inhibition with AZD1208 to prevent resistance to osimertinib in EGFR mutant NSCLC
J. Bracht¹, N. Karachaliou¹, J. Berenguer¹, I. Attili², M. Ito³, C. Codony-Servat¹, J. Codony-Servat¹, M. Filipiska⁴, N. Gil⁵, R. Rosell⁶; ¹Barcelona, ES, ²Padova, IT, ³Hiroshima, JP, ⁴Gdansk, PL, ⁵Lisboa, PT, ⁶Badalona, Barcelona/ES
- 12:30 - 12:30 25P - A non pathway-specific approach in EGFR and KRAS mutant or squamous cell histology non-small cell lung cancer (NSCLC)
M. Ito¹, C. Codony-Servat², J. Codony-Servat², I. Attili³, J. Berenguer², J. Bracht², N. Gil⁴, M. Okada¹, N. Karachaliou², R. Rosell⁵; ¹Hiroshima, JP, ²Barcelona, ES, ³Padova, IT, ⁴Lisboa, PT, ⁵Badalona, Barcelona/ES
- 12:30 - 12:30 26P - Incidence of T790M mutations after progression on first Line EGFR TKIS in Advanced NSCLC: Real Time data from a tertiary cancer institute in North India.
U. Batra¹, P. Jain², P. Babu², M. Sharma²; ¹New Delhi, Rohini/IN, ²New Delhi, IN
- 12:30 - 12:30 27P - ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients



G. Metro¹, R. Chiari², D. Giannarelli³, A. Sidoni², G. Bellezza²; ¹Perugia, (PG)/IT, ²Perugia, IT, ³Roma, IT

- 12:30 - 12:30 28P - The study of ALK rearrangement in advanced primary non-small cell lung cancer and associated metastatic lesions
C. Xu¹, W. Wang², W. Zhuang², Y. Tian², J. Zhang³, M. Fang², Y. Chen¹, G. Chen², T. Lv⁴, Y. Song⁴; ¹Fuzhou, CN, ²Hangzhou, CN, ³Taiyuan, CN, ⁴Nanjing, CN
- 12:30 - 12:30 29P - Preliminary assessment of a targeted break-point NGS assay for ALK gene fusion detection in lung adenocarcinoma samples from Chilean patients
M. Freire, R. Lizana, L. Ramos, G. Sepúlveda, A. Blanco, S. Chernilo, O. Arén, C. Fernández, R. Armisen; Santiago, CL
- 12:30 - 12:30 30P - Feasibility of anti-ROS1 SP384 for Detection of ROS1 Protein
I. Menzi¹, B. Richardson², C. Le², D. Smith², A. Hanlon Newell², C. Bell², G. Pate², R. Huang²; ¹Tucson, US, ²Tucson, AZ/US
- 12:30 - 12:30 31P - Analysis of ROS1 rearrangement non-small cell lung cancer cell blocks from pleural effusion
W. Wang¹, C. Xu², W. Zhuang¹, Y. Tian¹, J. Xu³, M. Fang¹, Y. Chen², G. Chen¹, T. Lv⁴, Y. Song⁴; ¹Hangzhou, CN, ²Fuzhou, CN, ³Hefei, CN, ⁴Nanjing, CN
- 12:30 - 12:30 32P - Serum Circulating Cell Free DNA As Potential Diagnostic And Prognostic Biomarker In Non Small Cell Lung Cancer
A. Alhanafy, S. El Shafei, M. Habib, R. Abdellatif, M. Haggag; Shebin El Kom, EG
- 12:30 - 12:30 33P - Expression of Biomarkers IDH1, CEA, TPA and CYFRA21-1 in peripheral blood and tissue of Non Small Cell Lung Carcinoma Patients detected by Real-time PCR.
A. Mishra, N. Singh, D. Sahu, S. Kumar; Lucknow, IN
- 12:30 - 12:30 34P - Recommendations for EGFR mutation testing with a fast and fully automated sample-to-result system: how to optimize DNA input instead of using lung cancer tissue?
C. Chapusot, Dijon, FR
- 12:30 - 12:30 37P - Epidemiological and Mangement of Bronchopulmonary carcinoma in Eastern Morocco about 738 Cases
I. Alloubi, K.Y. Belmokhtar, M. Bellaoui; Oujda, MA
- 12:30 - 12:30 38P - Survival of lung cancer: Bangladesh Perspective
R. Parveen¹, P. Akhtar², N. Khatun², M. Islam²; ¹Singapore, SG, ²Dhaka, BD
- 12:30 - 12:30 39P - Lung cancer in Morocco: results of a retrospective study
A. Haimer¹, F. Habib², A. Soulaymani¹, A. Mokhtari¹, H. Hami¹; ¹Kenitra, MA, ²Rabat, MA
- 12:30 - 12:30 40P - Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status



A. Matutino¹, E. Kornaga², M. Dean², A.A. Pereira³, G. Bebb²; ¹São Paulo, SP/BR, ²Calgary, AB/CA, ³Houston, TX/US

12:30 - 12:30 41P - Gender Based Variations In Presentation And Management Of Lung Cancer At A South Asian Tertiary Referral Centre

V. Vashistha¹, C. Choudhari², A. Garg², A. Gupta², G. Parthasarathy³, C. Mohan⁴, K. Madan², V. Hadda², G.C. Khilnani², A. Mohan⁴; ¹Durham, US, ²New Delhi, IN, ³Cleveland, US, ⁴Delhi, IN

12:30 - 12:30 42P - Is There a Delay in Diagnosis of Lung Cancer in Women?

Y. Tolwin¹, B. Silverman², N. Peled³; ¹Tel Aviv, IL, ²Jerusalem, IL, ³Beer Sheva, IL

12:30 - 12:30 43P - A network-based signature to predict the survival of non-smoking lung adenocarcinoma

Q. Mao, F. Jiang, L. Xu; Nanjing, CN

12:30 - 12:30 44P - A large population-based study on large cell neuroendocrine lung cancer: a SEER database analysis.

X. Fu, H. Zhang, Y. Yang, M. Liu, J. Lu, X. Liang, K. Nan, Y. Yao, T. Tian; Xi'an, CN

12:30 - 12:30 45P - Yoga as a powerful tool for smoking cessation – Convincing results of a community based randomized controlled trial

A. Aggarwal, Gurugram, IN

12:30 - 12:30 46P - Ban on gutka (a popular smokeless tobacco product) in India had negligible impact on smoking prevalence, large scale household survey in Delhi finds out

G. Kumar, P. Kumar; Ahmedabad, IN

12:30 - 12:30 48P - Clinical characteristics of Korean lung cancer patients with programmed death-ligand 1 expression

H. Park, Hwasun, KR

12:30 - 12:30 49P - Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: a systematic review and meta-analysis

J.H. Chang, Y.J. Ryu, J.H. Lee; Seoul, KR

12:30 - 12:30 50P - The expression and significance of miR-146a and miR-146b in BALB/c mice pulmonary precancerous lesions induced by fine particulate matter

T. Hou, G. Wang; Beijing, CN

12:30 - 12:30 53P - Lung Cancer: Beyond EGFR and ALK dichotomy

C. Satheesh¹, A. Bhatt², M. Singhal³, R. Aarthi⁴, K. Shubham⁴, G. Madhura⁴, V. Maka¹, R. Naik¹, S. Iyer⁴, G. sHAFI⁴; ¹Bangalore, IN, ²Pune, IN, ³New Delhi, IN, ⁴Mumbai, IN

12:30 - 12:30 54P - Epidermal Growth Factor Receptor Expression (EGFR) In Serum As A Marker Of Treatment Response And Survival In Advanced Squamous Cell Lung Cancer

A. Mohan¹, A. Ansari², M. Masroor², A. Saxena², K. Luthra², R. Pandey², D. Jain², R. Kumar², G.C. Khilnani², R. Guleria²; ¹Delhi, IN, ²New Delhi, IN



- 12:30 - 12:30 56P - Plasma circulating ctDNA: Potential biomarker in non-small cell lung carcinoma and clinical significance
V. Goel¹, S. Tiwari², V. Talwar¹, N. Pattnaik³, P. Dash², S. Raina², M. John²; ¹New Delhi, Rohini/IN, ²New Delhi, IN, ³Delhi, IN
- 12:30 - 12:30 57P - Targeted sequencing of plasma-derived cfDNA in patients with metastatic NSCLC
R. Pasquale, F. Bergantino, F. Fenizia, L. Forgione, C. Roma, A. De Luca, G. Rocco, A. Morabito, N. Normanno; Napoli, IT
- 12:30 - 12:30 58P - Co-treatment of trametinib (MEK inhibitor) with TPX-0005 (Src/FAK/JAK2 inhibitor) synergistic in KRAS mutant NSCLC cell lines and CDCP1 acts as a biomarker in KRAS mutant patients (p)
C. Codony-Servat¹, M. Llanos Gil Moreno¹, J. Bracht¹, I. Attili², C. Lazzari³, V. Gregorc³, M. Ito⁴, S. Viteri¹, N. Karachaliou¹, R. Rosell⁵; ¹Barcelona, ES, ²Padova, IT, ³Milan, IT, ⁴Hiroshima, JP, ⁵Badalona, Barcelona/ES
- 12:30 - 12:30 59P - Circulating microRNAs as novel predictive markers of afatinib efficacy in squamous cell lung cancer (SCC): an exploratory sub-analysis of the LUX-Lung 8 trial
Y. Gaston Math¹, P. Fogel¹, S. Martin-Lannerée¹, C. Marcaillou¹, E. Lallet¹, N. Krämer², N. Gibson³, F. Solca⁴, E. Ehrnrooth⁵, J. Cadranell¹; ¹Paris, FR, ²München, DE, ³No City Provided, NA, ⁴Vienna, AT, ⁵Copenhagen, DK
- 12:30 - 12:30 60P - Circulating miR-31 as a predictive marker of EGFR TKI treatment efficacy in squamous cell lung cancer (SCC): a sub-analysis of the LUX-Lung 8 trial
Y. Gaston Math¹, P. Fogel¹, S. Martin-Lannerée¹, C. Marcaillou¹, E. Lallet¹, N. Krämer², N. Gibson³, F. Solca⁴, E. Ehrnrooth⁵, J. Cadranell¹; ¹Paris, FR, ²München, DE, ³No City Provided, NA, ⁴Vienna, AT, ⁵Copenhagen, DK
- 12:30 - 12:30 61P - MiR-125b plays a tumor suppressor role in inflammation-related Non-small cell lung cancer via repressing IGF-1 signal pathway
Y. Zhang, B. Han, S. Hu, Y. Lou, T. Chu, J. Qian, Q. Chang; Shanghai, CN
- 12:30 - 12:30 62P - MAP kinase signaling pathway in pulmonary adenocarcinomas: a study from India
V. Singh, P. Malik, D. Jain; New Delhi, IN
- 12:30 - 12:30 63P - Prevalence and spectrum of germline mutations among patients with familial lung cancer
M. Kanwal, Dera Ghazi Khan, Yunnan/PK
- 12:30 - 12:30 64P - Cisplatin-Resistant Phenotype: Characterization, adaptation to EGFR signaling and sensitivity to EGFR inhibitors in NSCLC cells
V. Pamidiboina¹, F. Tian², R. Kiefel², M. Schaule², R.M. Huber²; ¹Muenchen, DE, ²München, DE
- 12:30 - 12:30 65P - Fatty acid synthase (FASN) inhibition effect on EGFR TKIs sensitive and resistant cells
S. Ruiz Martínez, J. Bosch-Barrera, M. Planas, L. Feliu, R. Porta-Balanya, T. Puig; Girona, ES
- 12:30 - 12:30 66P - PALB2 mRNA Expression as a Predictive Marker in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) Treated with Docetaxel-Cisplatin



N. Karachaliou¹, J. Berenguer¹, I. Chaib², J.L. Ramirez Serrano², M.T. Moran Bueno³, B. Massuti Sureda⁴, S. Calabuig Fariñas⁵, C. Camps⁵, M. Provencio Pulla⁶, R. Rosell³; ¹Barcelona, ES, ²Badalona, ES, ³Badalona, Barcelona/ES, ⁴Alicante, ES, ⁵Valencia, ES, ⁶Majadahonda, Madrid/ES

- 12:30 - 12:30 67P - The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
R. Grinberg¹, L. Roisman¹, S. Geva², L. Soussan-Gutman³, A. Dvir³, R. Yair³, T. Twito³, R. Larman⁴, N. Peled¹; ¹Beer Sheva, IL, ²Petah Tikva, IL, ³Shoham, IL, ⁴Redwood City, CA/US
- 12:30 - 12:30 68P - In vivo study of a novel chemoablative, thermoresponsive hydrogel for intratumoural administration in a murine A549 xenograft model
S. Rossi, B. Ryan, H. Kelly; Dublin, IE
- 12:30 - 12:30 69P - The diabetes drug Canagliflozin sensitizes Non-Small Cell Lung Cancer (NSCLC) to radiotherapy and chemotherapy.
T. Tsakiridis, L. Villani, L. Broadfield, K. Marcinko, E. Tsakiridis, P. Ellis, P. Muti, G. Steinberg; Hamilton, CA
- 12:30 - 12:30 70P - Immunological efficacy of anti-tumor dendritic cell vaccine application in patients with non-small cell lung cancer
O. Gorbach, N. Khranovska, O. Skachkova, M. Inomistova, V. Sovenko, A. Ganul, V. Orel; Kiev, UA
- 12:30 - 12:30 73P - PET and neck US for the detection of cervical lymphadenopathy in patients with lung cancer and mediastinal lymphadenopathy
M. Ahmed, Galway, IE
- 12:30 - 12:30 74P - Spatial concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to 18F-FLT PET Images: A Basic Study Guided for PET-based Radiotherapy Dose Painting
C. Li, X. Meng; Jinan, CN
- 12:30 - 12:30 76P - Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
D. Vuong, M. Bogowicz, M. Huellner, P. Veit-Haibach, N. Andratschke, J. Unkelbach, M. Guckenberger, S. Tanadini-Lang; Zürich, CH
- 12:30 - 12:30 77P - Is there an incremental benefit with 68 Ga DOTA PET/CT in staging of broncho-pulmonary carcinoid tumors?
G. Karimundackal, Mumbai, IN
- 12:30 - 12:30 79P - Small cell lung cancer in the Young: Characteristics, Timeliness, and Outcome Data
S. Jiang, Y. Han, Y. Huang, X. Hao, J. Li, X. Hu, Z. Xiao, H. Wang, Y. Wang, Y. Shi; Beijing, CN
- 12:30 - 12:30 80P - Understanding the patient perspective of small cell lung cancer (SCLC)
A. Rydén¹, S. Ollis², E. Love², A. Shields², H. Jiang³, P. Dennis³; ¹MÖlndal, SE, ²Boston, MA/US, ³Gaithersburg, MD/US
- 12:30 - 12:30 81P - The influence of comorbidity on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) compared to Non-Small Cell Lung Cancer (NSCLC)



A. Vedadi, S. Shakik, M..C. Brown, W. Xu, F. Shepherd, N. Leighl, P. Bradbury, G. Liu, G. O'Kane;
Toronto, CA

- 12:30 - 12:30 82P - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns among Patients with Extensive Disease Small Cell Lung Cancer
I. Uthman, M. Hassan; Ismailia, EG
- 12:30 - 12:30 83P - Radiotherapy improves the survival of patients with extensive disease small cell lung cancer: a propensity matched analysis of Surveillance, Epidemiology, and End Results database
R. Zhang, P. Li, Q. Li, Y. Qiao, T. Xu, Q. Song, Z. Fu; Wuhan, CN
- 12:30 - 12:30 84P - Patterns of Care for Patients with Small Cell Lung Cancer: A Survey of German Radiation Oncology Institutions on Recommendations for Prophylactic Cranial Irradiation
C. Eze, O. Roengvoraphoj, M. Dantes, R. Abdo, N. Schmidt-Hegemann, C. Belka, F. Manapov; Munich, DE
- 12:30 - 12:30 85P - Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer (ES-SCLC): a tertiary cancer centre experience
A. Srivastava, K. Shelly, F. Lin; Hamilton, NZ
- 12:30 - 12:30 86P - Prophylactic Cranial Irradiation in SCLC: A Survey of German Radiation Oncology Institutions on Recommendations for Brain Imaging
C. Eze, O. Roengvoraphoj, M. Dantes, R. Abdo, N. Schmidt-Hegemann, C. Belka, F. Manapov; Munich, DE
- 12:30 - 12:30 87P - Assessment of the Prognostic Utility of the Enumeration of Circulating Tumour Cells at the End of Treatment and Disease Relapse in Small Cell Lung Cancer Patients.
A. Vickers¹, A. Xenofontos¹, L. Carter¹, R. Bernabe², M. Carter¹, L. Franklin¹, K. Morris¹, J. Pierce¹, C. Dive¹, F. Blackhall¹; ¹Manchester, GB, ²Sevilla, ES
- 12:30 - 12:30 88P - Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, Phase 2/3 study
M. Edelman¹, O. Juan², A. Navarro³, G. Golden⁴, A. Saunders⁴; ¹Philadelphia, PA/US, ²Valencia, ES, ³Barcelona, ES, ⁴Durham, US
- 12:30 - 12:30 89P - The Role of Palliative Care In Extensive Stage Lung Cancer
Y. Ahmed, Sligo, IE
- 12:30 - 12:30 90P - Study of Intestinal Flora Differences Between Small Cell Lung Cancer Patients and Healthy People
L. Zhang¹, J. Chen²; ¹Wuhan, CN, ²Dalian, CN
- 12:30 - 12:30 92P - Expression of TNFR11 in Serum Is Correlated with the Significant Risk of Subcentimeter Lung Adenocarcinoma
Y. Zhang, B. Han, B. Sun, K. Yu, T. Chu, J. Qian, Q. Chang; Shanghai, CN
- 12:30 - 12:30 93P - DNA damage repair protein expression and EGFR gene status in NSCLC
J. Wang¹, W. Luo²; ¹Chengdu, CN, ²Chongqing, CN



- 12:30 - 12:30 94P - Lung cancer recurrence in patients with pre-operative circulating tumor DNA and elevated tumor markers
S. Isaksson, A. George, M. Jönsson, H. Cirenajwis, H. Brunnström, P. Jönsson, J. Staaf, L. Saal, M. Planck; Lund, SE
- 12:30 - 12:30 95P - Intubated Versus Nonintubated General Anesthesia for Minimally Invasive VATS in Octogenarians
N. Ilic, D. Ilic, J. Juricic, D. Krnic, N. Frleta Ilic, I. Simundza, D. Orsulic; Split, HR
- 12:30 - 12:30 96P - The role of bronchial stump reinforcement by flap in prevention of broncho-pleural fistula after major lung resections
F. Caushi, I. Skenduli, A. Mezini, A. Hatibi, H. Hafizi, S. Bala, E. Hysa, F. Kokiqi; Tirana, AL
- 12:30 - 12:50 97P - Multistep prediction of cardio-pulmonary morbidity after lung cancer surgery
N. Lukavetsky, R. Litviniak, I. Hipp, T. Fetsych; Lviv, UA
- 12:50 - 12:50 98P - Trends in and Impact of Hospital-acquired Adverse Events in Patients with Lung Cancer undergoing Lung Resection
A. Gupta¹, K. Mara², K. Kernstine³, S. Khanna², D. Gerber³; ¹Dallas, US, ²Rochester, MN/US, ³Dallas, TX/US
- 12:50 - 12:50 100P - Prognostic factors in surgically resected N2 non-small cell lung cancer: Significance of the subcarinal node
R. Qiao, J. Xu, Y. Zhang, W. Yang, B. Zhang, S. Wang, R. Zhong, B. Han; Shanghai, CN
- 12:50 - 12:50 101P - Overtreatment in early lung cancer: survival in dependence of pathological confirmation
F. Zehentmayr¹, M. Sprenger², G. Fastner¹, F. Sedlmayer¹; ¹Salzburg, AT, ²Graz, AT
- 12:50 - 12:50 102P - Stereotactic lung radiotherapy for early-stage NSCLC – an institution's experience
N. Ferreira, C. Travancinha, T. Antunes, J. Fonseca, M. Labareda, F. Santos; Lisbon, PT
- 12:50 - 12:50 103P - Stereotactic body radiotherapy followed by radiofrequency ablation for inoperable stage Ib non-small cell lung cancer
H. Ding, S. Chen, T. Chen, M. Su, C. Zhu, Q. Zheng; Nanjing, CN
- 12:50 - 12:50 104P - Adjuvant chemotherapy may improve prognosis in surgically resected stage I NSCLC with lymphovascular invasion
S. Wang, J. Xu, F. Qian, W. Yang, B. Zhang, J. Qian, R. Qiao, B. Han; Shanghai, CN
- 12:50 - 12:50 105P - Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected non-small cell lung cancer
R. Dokuni¹, M. Tachihara², S. Tokunaga², K. Okuno³, M. Yamamoto¹, K. Kobayashi¹, Y. Tanaka¹, Y. Funada³, Y. Maniwa¹, Y. Nishimura²; ¹Kobe, JP, ²Kobe, Hyogo/JP, ³Takatsuki, JP
- 12:50 - 12:50 106P - The Value of Adjuvant Chemotherapy in Patients with Resected Stage IB Solid Predominant and Solid Non-Predominant Lung Adenocarcinoma
S. Cao, J. Xu, H. Zhong; Shanghai, CN



- 12:50 - 12:50 107P - Meta analysis on defining optimal follow up of patients with early stage NSCLC after definitive therapy.
D. Wankhede, Delhi, IN
- 12:50 - 12:50 108TiP - A multi-center, prospective, randomized controlled clinical trial: comparison between wedge resection and segmentectomy in the surgical treatment of ground glass opacity-dominant stage IA non-small cell lung cancer
L. Liu, H. Liao; Chengdu, CN
- 12:50 - 12:50 113P - Exosomal miRNAs in peripheral blood as novel diagnostic biomarkers of radioresistant lung adenocarcinoma
C. Zhu¹, L. Wang¹, Q. Zhang¹, H. Xu¹, J. Tong¹, Y. Wan², Q. Zheng¹; ¹Nanjing, CN, ²University Park, PA/US
- 12:50 - 12:50 114P - Evaluation of pulmonary function parameters after moderate hypofractionated image-guided thoracic irradiation in locally-advanced node-positive non-small cell lung cancer patients with very limited lung function
F. Manapov¹, O. Roengvoraphoj¹, J. Taugner², M. Dantes¹, C. Wijaya², C. Belka¹, C. Eze¹; ¹Munich, DE, ²München, DE
- 12:50 - 12:50 115P - Heart and pulmonary artery radiation doses in non-small cell lung cancer
K. Thippu Jayaprakash, J. Rubasingham, C. Ingle, D. Muthukumar; Colchester, GB
- 12:50 - 12:50 116P - Comparison of Conformity and Homogeneity Index Values of VMAT and non-VMAT Techniques Used in Lung Cancer Radiotherapy
A. Ozen, M. Akcay, K. Duruer, O. Bozdogan, I. Surenkok, D. Etiz; Eskisehir, TR
- 12:50 - 12:50 117P - Feasibility of moderate hypofractionated image-guided thoracic irradiation for locally-advanced node-positive non-small cell lung cancer patients with very limited lung function
F. Manapov¹, O. Roengvoraphoj¹, J. Taugner², M. Dantes¹, C. Wijaya², C. Belka¹, C. Eze¹; ¹Munich, DE, ²München, DE
- 12:50 - 12:50 118P - A Comparative Study of Sequential Chemoradiation vs Concurrent Chemoradiation vs Concurrent Chemoradiation followed by Consolidation Chemotherapy in Unresectable NSCLC
A. Datta, K. Choudhury, A. Majumdar; Kolkata, IN
- 12:50 - 12:50 119P - Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non Small Cell Lung Cancer: A One Year Phase II Trial at a Low Resource Setting
M. Shuayb, M. Shahi, M. Hossen; Dhaka, BD
- 12:50 - 12:50 120P - Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NCSLC)
N. Jokhadze, I. Kiladze, L. Katselashvili, M. Kacharava, N. Jankarashvili, I. Zumbadze, N. Kalandarishvili, T. Melkadze, E. Gogua; Tbilisi, GE
- 12:50 - 12:50 121P - Primary Surgery followed by Chemotherapy versus definitive concurrent Chemoradiotherapy in locally advanced non-small-cell lung cancer
I. Kiladze, V. Kuchava, N. Joxadze, L. Katselashvili, T. Melkadze; Tbilisi, GE



- 12:50 - 12:50 122P - Pathological response rates after induction radio-chemotherapy in stage III NSCLC.
F. Casas¹, D. Sanchez¹, D. Martínez¹, M. Boada¹, N. Vilariño¹, R. Martín¹, P. Paredes¹, I. Volmer¹, K.S. Cortés¹, M. Parera²; ¹Barcelona, ES, ²Vic, ES
- 12:50 - 12:50 124P - Cardiac events in stage III non-small cell lung cancer (NSCLC): an attention shift to cardio-oncology collaboration.
J. Degens¹, D. De Ruyscher¹, B. Kietselaer², A. Schols¹, A. Dingemans¹; ¹Maastricht, NL, ²Heerlen, NL
- 12:50 - 12:50 125P - Brain metastases in patients with stage N2 non-small cell lung cancer
C. Lowrie, E. McCully, S. Ansel, P. McLoone, N. Mohammed; Glasgow, GB
- 12:50 - 12:50 126TiP - SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
S. Rothschild¹, A. Zippelius¹, S. Savic Prince¹, M. Gonzalez², W. Weder³, A. Xyrafas⁴, C. Rusterholz⁴, M. Pless⁵; ¹Basel, CH, ²Lausanne, CH, ³Zürich, CH, ⁴Bern, CH, ⁵Winterthur, CH
- 12:50 - 12:50 127TiP - Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574).
T. Tsakiridis, N. Isfahanian, N. Nguyen, J. Wright, W. Hanna, A. Swaminath, Y. Shargal, J. Agzaraian, M. Wierzbicki, T. Chow; Hamilton, CA
- 12:50 - 12:50 145P - Impact of Next-Generation Sequencing on Survival in Lung Cancer
S. Geva¹, A. Belilovski Rozenblum¹, L. Roisman², M. Ilouze¹, E. Dudnik¹, A. Zer¹, O. Rotem¹, N. Peled²; ¹Petah Tikva, IL, ²Beer Sheva, IL
- 12:50 - 12:50 146P - The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer
S. Geva¹, A. Belilovski Rozenblum¹, R. Grinberg², A. Dvir³, L. Soussan-Gutman³, L. Roisman², E. Dudnik¹, A. Zer¹, O. Rotem¹, N. Peled²; ¹Petah Tikva, IL, ²Beer Sheva, IL, ³Shoham, IL
- 12:50 - 12:50 147P - Clinical Testing of ctDNA from NSCLC Patients Using A 17-Gene Liquid Biopsy Mutation Panel
D. Eberhard, J. Bennett, D. Davison, C. Hammond, A. Petty, J. Pluenneke, A. Dei Rossi, G. Alexander, D. Paragas, M. Lopatin; Redwood City, CA/US
- 12:50 - 12:50 148P - Method comparison for detection of epidermal growth factor receptor (EGFR) T790M mutation in matched biopsied tumour sections and plasma samples
J. Longshore¹, S. Patel², B. Collins², M. Cantarini³, S. Jenkins⁴; ¹Charlotte, US, ²Cambridge, GB, ³Macclesfield, Cheshire/GB, ⁴Macclesfield, GB
- 12:50 - 12:50 149P - Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma - a single centre experience exploring effects of dose-reduction
N. Tokaca¹, M. O'Brien¹, J. Bhosle², N. Yousaf¹, R. Kumar², S. Popat¹, D. Walder²; ¹London, GB, ²Sutton, GB



- 12:50 - 12:50 150P - Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study
M. Gottfried¹, S. Keren Rosenberg², J. Dudnik³, M. Wollner², J. Bar⁴, A. Onn⁴, O. Frenkel⁵, N. Maimon⁶; ¹Kfar Saba, IL, ²Haifa, IL, ³Beer Sheva, IL, ⁴Ramat Gan, IL, ⁵Hod Hasharon, IL, ⁶Rishon Le Zion, IL
- 12:50 - 12:50 151P - Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results
K. Gupta, A. Joshi, V. Noronha, S. Parthiban, V. Patil, A. Janu, R. Kaushal, K. Prabhash; Mumbai, IN
- 12:50 - 12:50 152P - Impaired liver function was associated with PFS of EGFR TKI treatment
Q. Zhu, Y. Chen, Y. Hong, Z. Ding; Chengdu, CN
- 12:50 - 12:50 153P - EGFR T790M co-exists with sensitive mutations in the same cell group in lung adenocarcinoma patients
X. Shi, S. Wu, H. Wang, Z. Liang, X. Zeng; Beijing, CN
- 12:50 - 12:50 154P - CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: real world data
R. Devjak¹, N. Turnsek Hitij², K. Mohorcic², M. Rajer², T. Cufer²; ¹Ljubljana, SI, ²Golnik, SI
- 12:50 - 12:50 155P - Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models
F. Morgillo¹, C.M. Della Corte¹, R. Alfieri², P. Petronini², S. La Monica², F. Papaccio¹, F. Ciardiello¹; ¹Napoli, IT, ²Parma, IT
- 12:50 - 12:50 156P - ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain
D. Vicente Baz¹, A. Paredes Lario², M.T. Moran Bueno³, B. Massuti Sureda⁴, N. Reguard⁵, R. Álvarez⁶, A. Insa Molla⁷, O. Juan⁸, G. Marquez⁹, M. Provencio Pulla¹⁰; ¹Sevilla, ES, ²San Sebastian, ES, ³Badalona, Barcelona/ES, ⁴Alicante, ES, ⁵Barcelona, ES, ⁶Madrid, ES, ⁷Valencia, Valencia/ES, ⁸Valencia, ES, ⁹Ciudad De Buenos Aires, AR, ¹⁰Majadahonda, Madrid/ES
- 12:50 - 12:50 157P - Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: a Phase IV study
S. Thongprasert¹, S. Geater², D. Clement³, A. Abdelaziz⁴, J. Reyer-Igama⁵, D. Jovanovic⁶, S. Suresh⁷, A. Cseh⁸, R. Gaafar⁹; ¹Maidenhead, GB, ²Songkla, TH, ³Iasi, RO, ⁴Alexandria, EG, ⁵Baguio City, PH, ⁶Belgrade, RS, ⁷Singapore, SG, ⁸Vienna, AT, ⁹Cairo, EG
- 12:50 - 12:50 158P - Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: overview of clinical data
A. Märten¹, N. Yamamoto², C. Yu³, S. Ou⁴, C. Zhou⁵, Y. Wu⁶; ¹Ingelheim Am Rhein, DE, ²Wakayama, JP, ³Taipei, TW, ⁴Orange, CA/US, ⁵Shanghai, CN, ⁶Guangzhou, CN
- 12:50 - 12:50 159P - Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: a Spanish retrospective multicentre study



M.T. Moran Bueno¹, C. Aguado², M. Dómine², A. Gomez Rueda², A. Calles², S.M. Cedres³, N. Viñolas³, D. Isla⁴, R. Palmero⁵, M. Sereno Moyano²; ¹Badalona, Barcelona/ES, ²Madrid, ES, ³Barcelona, ES, ⁴Zaragoza, ES, ⁵L'hospitalet De Llobregat, Barcelona, ES

- 12:50 - 12:50 160P - Real world study of lung squamous cell carcinoma patients with EGFR mutation treated with EGFR-TKI
L. Miao¹, G. Lin², Y. Wu³, J. Chen⁴, X. Ai⁵, M. Yuan⁶, R. Chen⁶; ¹Nanjing, CN, ²Fuzhou, CN, ³Dongguan, CN, ⁴Changsha, CN, ⁵Shanghai, CN, ⁶Beijing, CN
- 12:50 - 12:50 161P - The survival of advanced non small cell lung cancer with Epidermal Growth Factor Receptor in Thailand, A single institution review
A. Supavavej, M. Tandhansakul; Bangkok, TH
- 12:50 - 12:50 162P - Responses to EGFR TKIs and ALK TKIs in advanced NSCLC patients harboring concomitant EGFR and ALK alterations
S. Wang, T. Chu, B. Zhang, B. Han, B. Yan, R. Qiao; Shanghai, CN
- 12:50 - 12:50 163P - The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network
J. Roeper¹, M. Netchaeva², A. Lueers³, M. Falk⁴, M. Tiemann¹, C. Wesseler⁵, G. Wiest⁵, S. Sackmann², D. Ukena², F. Griesinger³; ¹Berlin, DE, ²Bremen, DE, ³Oldenburg, DE, ⁴Hamburg, Hamburg/DE, ⁵Hamburg, DE
- 12:50 - 12:50 164P - Feasibility of Liquid Biopsy Using Plasma and Platelets for Detection of ALK Rearrangements in Non-Small Cell Lung Cancer
C. Park¹, H. Park¹, H. Cho¹, Y. Choi², I. Oh¹, Y. Kim¹; ¹Hwasun, KR, ²Gwangju, KR
- 12:50 - 12:50 165P - Analysis of our experience of ROS-1 patients in Advanced NSCLC
N. Pande, A. Joshi, V. Noronha, V. Patil, A. Mahajan, K. Prabhash; Mumbai, IN
- 12:50 - 12:50 166P - Evidence-based conclusions and inclinations of pemetrexed, taxane and bevacizumab in advanced lung cancer
S. Shaheen¹, L. Ji², J. Morgan², S. Otoukesh², H. Mirshahidi²; ¹Loma Linda, US, ²Loma Linda, CA/US
- 12:50 - 12:50 167P - Efficacy of Pemetrexed-Based Chemotherapy in Advanced Lung Adenocarcinoma Patients with ROS-1 Rearrangement
B. Zhang, T. Chu, J. Xu, Y. Zhang, B. Yan, Y. Dong, J. Qian, R. Qiao, S. Wang, B. Han; Shanghai, CN
- 12:50 - 12:50 168P - Pemetrexed dosing regimens in patients with advanced NSCLC
S. Visser¹, S. Koolen², P. de Bruijn², B. Stricker², R. Mathijssen², J. Aerts³; ¹Breda, NL, ²Rotterdam, NL, ³Rotterdam, Noord Brabant/NL
- 12:50 - 12:50 169P - Nephrotoxicity of pemetrexed maintenance in patients with advanced NSCLC: Two cohort studies
S. Visser¹, J. Huisbrink², N. Van 'T Veer¹, J. Van Toor², T. Van Boxem³, N. Van Walree¹, B. Stricker², J. Aerts⁴; ¹Breda, NL, ²Rotterdam, NL, ³Roosendaal, NL, ⁴Rotterdam, Noord Brabant/NL



- 12:50 - 12:50 170P - A Phase II Trial of Nab-Paclitaxel and Gemcitabine in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum Based Chemotherapy
Y. Hatakeyama¹, M. Tachihara², T. Kiri², A. Hata², T. Nagano², M. Yamamoto², K. Kobayashi², H. Ohnishi¹, N. Katakami², Y. Nishimura²; ¹Akashi, JP, ²Kobe, JP
- 12:50 - 12:50 171P - A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
Y. Kono¹, Y. Hattori¹, K. Nishino², R. Uozumi³, S. Itoh¹, T. Inoue², T. Kumagai², S. Morita³, F. Imamura², M. Satouchi¹; ¹Akashi, JP, ²Osaka, JP, ³Kyoto, JP
- 12:50 - 12:50 172P - Safety and Efficacy Phase 2 Study of nab-Paclitaxel Maintenance Treatment after nab-Paclitaxel plus Carboplatin in Stage IIIB/IV Non-small Cell Lung Cancer.
A. Nakao¹, J. Uchino², N. Nagata¹, K. Takayama², K. Watanabe¹, M. Fujita¹; ¹Fukuoka, JP, ²Kyoto, JP
- 12:50 - 12:50 173P - Apatinib plus S-1 shows encouraging response in advanced Non-small-Cell Lung Cancer as laterline chemotherapy.
Z. wu, J. Wu; Beijing, CN
- 12:50 - 12:50 174P - Aprepitant, palonosetron and dexamethasone proved effective to prevent chemotherapy-related nausea and vomiting in lung cancer
Y. Zhang, N. Yang, F. Zeng, F. Wu; Changsha, CN
- 12:50 - 12:50 175P - A prospective, randomized, double-blind study of pre-chemotherapy hydration with or without mannitol to prevent renal toxicity in non-small cell lung cancer (NSCLC) patients receiving cisplatin-gemcitabine chemotherapy:
N. Thavornpattanpong, Songkla, TH
- 12:50 - 12:50 176P - PrediCare: a New Diagnostic Tool Predicting Imminent Disease Progression in Advanced NSCLC Patients by Machine-Learning Integration of Three Serum Biomarkers
Y. Kogan¹, M. Kleiman¹, S. Shannon¹, M. Elishmereni¹, E. Taub¹, L. Aptekar², R. Brenner³, R. Berger⁴, H. Nechushtan², Z. Agur¹; ¹Bene Ataroth, IL, ²Jerusalem, IL, ³Holon, IL, ⁴Ramat Gan, IL
- 12:50 - 12:50 177P - Clinicopathologic characteristics in Large Cell Neuroendocrine Carcinomas of the Lung (LCNCL).The experience of one center.
M. Vaslamatzis¹, A. Laskarakis², T. Tegos¹, M. Pavlakis¹, T. Argyrakos¹, N. Alevizopoulos¹, C. Zoublios¹, E. Vasili¹, E. Gioti¹, K. Athanasiadi¹; ¹Athens, GR, ²Piraeus, GR
- 12:50 - 12:50 178P - Smo inhibitor LDE225 reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer(NSCLC) cells
Y. Yu, Y. Cao, B. Pan, S. Jin; Harbin, CN
- 12:50 - 12:50 179P - The cytoplasmic LKB1 promotes the growth of human lung adenocarcinoma by enhancing autophagy
M.J. Liu, L. Jiang, X. Fu, X. Liang; Xi'an, CN
- 12:50 - 12:50 180P - Significant Progress in Palliative Treatment of NSCLC over the last Decades – Correlation of Treatment Milestones with Survival in Unselected Patients



S. Rothschild¹, R. Nachbur¹, N. Herzog¹, J. Passweg¹, M. Pless²; ¹Basel, CH, ²Winterthur, CH

- 12:50 - 12:50 181P - Real-World Comparative Effectiveness of Treatment Sequences in Metastatic Non-Small Cell Lung Cancer with Squamous Histology
H. Yang¹, B. Levy², J. Signorovitch³, O. Patterson-Lomba³, C. Xiang³, M. Parisi⁴; ¹Boston, US, ²Washington, DC/US, ³Boston, MA/US, ⁴Summit, NJ/US
- 12:50 - 12:50 182P - Real world anti-PD-L1 treatment (tx) outcomes in a multinational European non-small cell lung cancer (NSCLC) cohort with focus on toxicity (tox) and brain metastases (BM): Preliminary data from an EORTC young investigators lung cancer group collaborative analysis
R. Tassi¹, F. Taylor², S. Canova³, L. Low⁴, O. Abdel-Rahman⁵, B. Hasan⁶, E. De Maio⁶, A. Levy⁷, B. Besse⁸, L. Hendriks⁹; ¹Firenze, IT, ²Sheffield, S. Yorks/GB, ³Monza, IT, ⁴Sheffield, GB, ⁵Cairo, EG, ⁶Brussels, BE, ⁷Villejuif, FR, ⁸Villejuif, CEDEX/FR, ⁹Maastricht, NL
- 12:50 - 12:50 183P - Progression of central nervous system metastases in advanced non-small cell lung cancer patients effectively treated with first-generation EGFR-TKI
M. Yu, Q. Zhao, Y. Li, S. Zhang, X. Zhou, J. Wang, Y. Wang, Y. Lu, Y. Liu; Chengdu, CN
- 12:50 - 12:50 184P - Clinico-radiological pattern of response to nivolumab in stage IV NSCL: a real life experience over two years.
M. Perna, V. Scotti, C. Muntoni, C. Moroni, F. Giannelli, D. Cozzi, F. Mazzoni, V. Bonti, D. Lavacchi, L. Livi; Firenze, IT
- 12:50 - 12:50 185P - Retrospective study of tumour responses and toxicities associated with anti- PD1 antibody therapy in elderly cancer patients(>75yo) in comparison to patients ≤ 75yo with metastatic non small cell lung cancer
L.C. CHONG¹, N. Corsini², J. Hogan-Doran², M. Brown²; ¹Adelaide, AU, ²Adelaide, SA/AU
- 12:50 - 12:50 186P - Thyroid Toxicity as an Immune-related Adverse Event in Patients with Non-Small Cell Lung Cancer During Treatment with Immune Checkpoint Inhibitors
K. Syrigos, A. Charpidou, A. Asimakopoulou, I. Vathiotis, I. Gkiozos, S. Tsagouli, P. Boura, D. Grapsa, E. Kotteas; Athens, GR
- 12:50 - 12:50 187P - Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response
J. Rogado¹, V. Pacheco Barcia¹, B. Vera¹, P. Toquero¹, R. Mondejar², A.I. Ballesteros Garcia¹, O. Donnay¹, N. Romero Laorden³, R. Colomer Bosch¹, J.M. Sánchez-Torres¹; ¹Madrid, ES, ²Cuenca, ES, ³Madrid, Madrid/ES
- 12:50 - 12:50 188P - Treatment switching-adjusted overall survival (OS) in KEYNOTE-024: first-line pembrolizumab versus chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)
M. Reck¹, D. Rodríguez-Abreu², A. Robinson³, R. Hui⁴, T. Csósz⁵, K. Vandormael⁶, W. Malbecq⁶, M..C. Pietanza⁷, J. Brahmer⁸; ¹Grosshansdorf, DE, ²Las Palmas, ES, ³Kingston, ON/CA, ⁴Westmead, NSW/AU, ⁵Szolnok, HU, ⁶Brussels, BE, ⁷Kenilworth, NJ/US, ⁸Baltimore, MD/US



- 12:50 - 12:50 189P - Are pretreatment neutrophil-lymphocyte ratio (NLR) , platelet-lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI) levels useful in predicting the outcomes of patients with advanced nonsmall-cell lung cancer?
B. Komurcuoglu¹, A. Evkan², G. Karakurt²; ¹Izmir, Karsiyaka/TR, ²Izmir, TR
- 12:50 - 12:50 190P - Are neutrophil-to-lymphocyte ratio (NLR) and neutrophil count percentage (NCP) predictors of Nivolumab outcome and toxicity in NSCLC?
J. Rogado¹, V. Pacheco Barcia¹, P. Toquero¹, B. Vera¹, R. Mondejar², N. Romero Laorden³, A.I. Ballesteros Garcia¹, O. Donnay¹, R. Colomer Bosch¹, J.M. Sánchez-Torres¹; ¹Madrid, ES, ²Cuenca, ES, ³Madrid, Madrid/ES
- 12:50 - 12:50 192P - KRAS as predictive biomarker of response to checkpoint inhibitors in NSCLC
A. Addeo, J. Torralvo, P. Dietrich; Geneva, CH
- 12:50 - 12:50 193TiP - Phase 3 Study of Epacadostat Plus Pembrolizumab With or Without Platinum-based Chemotherapy vs Pembrolizumab Plus Chemotherapy For First-Line Metastatic Non-Small Cell Lung Cancer (mNSCLC): ECHO-306/KEYNOTE-715
M. Garassino¹, S. Rubin², Y. Zhao², Y. Luo³, A. Samkari³, R. Hui⁴; ¹Milan, IT, ²Wilmington, DE/US, ³Kenilworth, NJ/US, ⁴Westmead, NSW/AU
- 12:50 - 12:50 194TiP - eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
L. Horn¹, Y. Wu², M. Reck³, C. Liang⁴, F. Tan⁵, K. Harrow⁴, V. Oertel⁴, G. Dukart⁴, T.S.K. Mok⁶; ¹Nashville, TN/US, ²Guangzhou, CN, ³Grosshansdorf, DE, ⁴Palm Beach Gardens, FL/US, ⁵Beijing, CN, ⁶Shatin, HK
- 12:50 - 12:50 195TiP - A Phase 3, Randomized, Double-Blind Study of Epacadostat Plus Pembrolizumab vs Pembrolizumab as First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC) Expressing High PD-L1 Levels (ECHO-305/KEYNOTE-654)
L. Paz-Ares¹, S. Rubin², Y. Zhao², L. Xu³, A. Samkari³, M. Awad⁴; ¹Madrid, ES, ²Wilmington, DE/US, ³Kenilworth, NJ/US, ⁴Boston, US
- 12:50 - 12:50 196TiP - CheckMate 384: A Phase 3b/4 Dose-Frequency Optimization Trial of Nivolumab in Advanced or Metastatic NSCLC
E. Garon¹, N. Reinmuth², R. Harris³, P. Mitchell⁴, J. Zhu⁵, G. Selvaggi⁶, S. Agrawal⁷, E. Pichon⁸; ¹Santa Monica, CA/US, ²Gauting, DE, ³Johnson City, NY/US, ⁴Melbourne, VIC/AU, ⁵Princeton, NJ/US, ⁶New York, NJ/US, ⁷Princeton, US, ⁸Tours, CEDEX 9/FR
- 12:50 - 12:50 197TiP - A Phase 1/2 trial of Selinexor combined with Docetaxel for Previously Treated, Advanced KRAS Mutant Non-small Cell Lung Cancer
A. Gupta¹, H. West², D.R. Camidge³, T. Stinchcombe⁴, L. Horn⁵, J. Saltarski¹, J. Bolluyt⁶, M. White⁶, D. Gerber⁶; ¹Dallas, US, ²Seattle, WA/US, ³Denver, CO/US, ⁴Durham, NC/US, ⁵Nashville, TN/US, ⁶Dallas, TX/US
- 12:50 - 12:50 198TiP - Afatinib plus EGF Pathway Targeting Immunization (EGF-PTI) as 1st line therapy for EGFR mutant NSCLC: the EPICAL study



N. Karachaliou¹, A. Cardona Zorrilla², D. Rodríguez-Abreu³, M. Cobo Dols⁴, N. Reguart Aransay¹, S. Viteri¹, J. Codony-Servat¹, M.A. Molina-Vila¹, E. D'Hondt⁵, R. Rosell⁶; ¹Barcelona, ES, ²Bogotá, CO, ³Las Palmas, ES, ⁴No City Provided, NA, ⁵Kruikebe, BE, ⁶Badalona, Barcelona/ES

- 12:50 - 12:50 199TiP - TTFIELDS concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase 3 LUNAR study
U. Weinberg¹, O. Farber², M. Giladi², Z. Bomzon², E. Kirson²; ¹Luzern, CH, ²Haifa, IL
- 12:50 - 12:50 201P - Isolation of Circulating Tumor Cells and Potential Heterogeneity Analysis in Advanced Non-Small Cell Lung Cancer
H. Zhang, Q. Zhang, J. Nong, J. Wang, Z. Yan, L. Yi, X. Cheng, Z. Liu, S. Zhang; Beijing, CN
- 12:50 - 12:50 202P - The clone evolutionary landscape and genomic characteristics of osteosarcoma and lung metastasis
J. Lai¹, C. Xu¹, W. Wang², Z. Song², Y. Chen¹, Y. Zhu³, S. Cai⁴, G. Chen², T. Lv⁵, Y. Song⁵; ¹Fuzhou, CN, ²Hangzhou, CN, ³Jiaying, CN, ⁴Shanghai, CN, ⁵Nanjing, CN
- 12:50 - 12:50 203P - Combined Pulmonary Metastasectomy and Chemotherapy in Patients with Colorectal Lung Metastases and Concurrent Extrapulmonary Disease
M. Faisal, I. Uthman, A. Abo Bakr; Ismailia, EG
- 12:50 - 12:50 204P - Clinicopathological Features, Treatment patterns and outcomes of Pulmonary Metastasectomy
P. Shivanna, S. Deo, N.K. Shukla, S. Bhorival, R. Thakur, S. Bakshi, R. Palaniappan, S. Kumar; New Delhi, IN
- 12:50 - 12:50 205P - RNA-seq analysis of lung adenocarcinomas reveals different circular RNA expression profiles between Non-metastatic and Metastatic patients
D. Wu¹, X. Qi¹, B. Qin²; ¹Xiamen, CN, ²Beijing, CN
- 12:50 - 12:50 206P - Isolated splenic metastasis from non-small cell lung cancer: Study of an extremely rare clinical entity with review of all cases reported in the literature
N. Mitsimponas¹, M. Mitsogianni², A. Giagounidis²; ¹Athens, GR, ²Düsseldorf, DE
- 12:50 - 12:50 207P - A comparison of outcomes of stereotactic body radiotherapy versus metastasectomy in patients with pulmonary metastases
Y.H. Lee¹, K.M. Kang¹, H. Choi¹, I.B. Ha¹, H. Jeong¹, J.H. Song², B.K. Jeong¹; ¹Jinju, KR, ²Changwon, KR
- 12:50 - 12:50 208P - Metastatic non-small cell lung carcinoma: About 420 cases
H. Loubna, Fez, MA
- 12:50 - 12:50 209P - The management of brain disease (BD) in ALK-rearranged non-small cell lung cancer (ALK NSCLC): Can systemic treatment delay the initiation of local treatments? Experience of the Ramón y Cajal University Hospital (RyCUH, Madrid)
R. Martín Huertas, I. Ciscar Garcia, C. Saavedra Serrano, J.J. Serrano Domingo, E. Corral de la Fuente, J.J. Soto Castillo, A. Gomez Rueda, M.E. Olmedo Garcia, P. Garrido Lopez; Madrid, ES



- 12:50 - 12:50 210P - Brain Oligometastases in NSCLC: Therapeutic Effect and Prognostic Factors of WBRT combined with Intracarotid Infusion of Elemenene
Y. XU, X. Lv, Y. Liu, B. Dong; Dalian, CN
- 12:50 - 12:50 211P - First Analysis of a Real World Study to Explore the Character and Treatment Outcome of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) on Non Small Cell Lung Cancer(NSCLC) with Brain Metastases(BM)
H. Zhang¹, L. Liu¹, C. Zhang², N. Zhang¹, H. Su¹, Y. Song¹, J. Min¹; ¹Xi'an, CN, ²Beijing, CN
- 12:50 - 12:50 212P - Clinical Experience and predictive factors of response to Whole Brain radiotherapy in metastatic lung cancer – A Single Institute experience
V. Pareek, R. Bhalavat, M. Chandra; Mumbai, IN
- 12:50 - 12:50 217P - Impact of VEGF and CD74 Expression on Response and Survival of Malignant Pleural Mesothelioma Patients Treated with Gemcitabine and Cisplatin; a phase II retrospective study
D. Soliman, M.A. Ellithy, A. Saad, M. Jassim, H. Abou Gabal, W. Osman; Cairo, EG
- 12:50 - 12:50 218P - Platinum-based Pemetrexed versus Platinum-based Gemcitabine for the Treatment of Patients with Malignant Pleural Mesothelioma: An Institutional Experience
S. Shahin, A. Saad, R. Ghali; Cairo, EG
- 12:50 - 12:50 219P - Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)
S. Cedres, F. Amair, A. Martinez-Marti, A. Navarro, N. Pardo, J. Remon-Masip, J.M. Miquel, G. Villacampa, R. Dienstmann, E. Felip Font; Barcelona, ES
- 12:50 - 12:50 220P - Effects of pifithrin- μ on the growth of acidity-tolerant malignant mesothelioma cells and epithelial-mesenchymal transition
S. Lee, Y. Lee; Cheonan, KR
- 12:50 - 12:50 221P - Treatment experience of Pleural Malignant Mesothelioma in a tertiary referral center in Mexico
A. Gutierrez¹, G. Nuñez-Cerrillo¹, Y.A. Remolina-Bonilla¹, A. Armengol-Alonso², R. Trejo-Rosales²; ¹Mexico City, MX, ²Ciudad De México, MX
- 12:50 - 12:50 222P - Women: the other face of malignant pleural mesothelioma
M. Brandão, M. Rocha, J. Silva, L. Nascimento, T. Gomes, B. Conde, A. Fernandes; Vila Real, PT
- 12:50 - 12:50 223P - Sarcomatoid lung carcinoma: An Uncommon and Deadly Entity
A. Sharma¹, E. Contreras², K. Sandoval², L. Nicholson³, J. Waalen³, M. Bhangoo³; ¹La Jolla, US, ²San Diego, CA/US, ³La Jolla, CA/US
- 12:50 - 12:50 224P - The role of surgery in the treatment of lung neuroendocrine tumors (NETs) based on a 3-years experience of a thoracic department
B. von Amann, C. Rodrigues, A. Ribeiro, C. Bárbara, F. Félix; Lisbon, PT
- 12:50 - 12:50 225P - Surgical experience of advanced Bronchopulmonary Carcinoids: an analysis from tertiary care hospital of North India



N. Kumar¹, S. Deo¹, N. Shukla¹, S. Boriwal¹, V. Kumar¹, P. Ramanathan¹, D. Jain², K. Madan², S. Kumar¹; ¹Delhi, IN, ²New Delhi, IN

- 12:50 - 12:50 226P - Accuracy of mutation analysis in small tissues from transbronchial lung biopsy with radial probe endobronchial ultrasound
M.K. Lee, J.S. Eom; Busan, KR
- 12:50 - 12:50 227P - Stereotactic Body Radiotherapy with Helical TomoTherapy for lung tumors: a single-center experience.
V. Figlia, F. Cuccia, V. Valenti, A. Tripoli, G. Terranova, A. Lo Casto, G. Failla, T. Cucchiara, G. Mortellaro, G. Ferrera; Palermo, IT
- 12:50 - 12:50 228P - Augmentation of NAD+ by NQO1 activation attenuates cisplatin-mediated hearing impairment
S. Yang, K.K. Kwon, H. So; Iksan, KR
- 12:50 - 12:50 229P - Clinical and Laboratory Markers of Prognosis in Lung Cancer Patients with Hypercalcemia
K. Syrigos, A. Ntineri, P. Bakakos, D. Grapsa, E. Dalakou, E. Kotteas, A. Charpidou; Athens, GR
- 12:50 - 12:50 230P - Experience with the implant of vascular access devices by medical oncologist in a non-surgical scenery
A. Revuelta, D. Rodríguez Rubí, L. Fárez, M.D.P. Solís, S. Fernández Arrojo, C. Iglesias Gómez, D. Gómez, J. del Río Fernández, A. Castillo Trujillo, E. Esteban González; Oviedo, ES
- 12:50 - 12:50 231P - Impact of the continuity of nursing care delivered by a pivot nurse in oncology on improving satisfaction and quality of life of patients with advanced lung cancer
E. Kassouf¹, M. Tehfe², M. Floresci², N. Blais²; ¹St-Charles-borromée, Quebec/CA, ²Montreal, QC/CA
- 12:50 - 12:50 232TiP - Lanreotide autogel/depot in lung neuroendocrine tumours: the randomized, double-blind, placebo-controlled, international phase 3 SPINET Study
X. Truong¹, D. Reidy-Lagunes², M. Kulke³, E. Wolin², S. Singh⁴, D. Ferone⁵, D. Hoersch⁶, A. Houchard¹, M. Caplin⁷, E. Baudin⁸; ¹Boulogne-Billancourt, FR, ²New York, US, ³Boston, MA/US, ⁴Toronto, Ontario/CA, ⁵Genova, IT, ⁶Bad Berka, DE, ⁷London, GB, ⁸Villejuif, FR

13:00 - 14:00 Industry Satellite Symposium 3 Room A

14:10 - 14:40 Keynote lecture Room B

14:10 - 14:40 Molecular and immuno landscaping in lung cancer
M. Sibilía, Vienna, AT



14:45 - 16:15 Proffered Paper 1 Room B

14:45 - 15:05 1100 - High-Dose Radiation Therapy Based on Normal Tissue Constraints with Concurrent Chemotherapy Improves Survival of Patients with Unresectable Stage III Non-Small Cell Lung Cancer
B. Li, Q. Zhao, M. Liu; Jinan, CN

15:05 - 15:25 1110 - Impact of cardiac doses on survival of non-small cell lung cancer (NSCLC) patients following radical accelerated radiotherapy
M. Hatton¹, S. Robinson¹, J. Bradshaw¹, S. Riley¹, T. Das², C. Lee², P. Fisher², E. Bates¹, S. Tozer-Loft¹, B. Tahir¹; ¹Sheffield, GB, ²Sheffield, South Yorkshire/GB

15:25 - 15:45 1310 - Radiotherapy improves the survival of patients with Stage IV non-small cell lung cancer: a propensity matched analysis of Surveillance, Epidemiology, and End Results database
R. Zhang, P. Li, Q. Li, Y. Qiao, T. Xu, Q. Song, Z. Fu; Wuhan, CN

14:45 - 16:15 Relevant biomarkers for the use of immune checkpoints Room C

14:45 - 15:00 Update on PD-L1 and other immunohistochemistry biomarkers
F. Hirsch, Denver, CO/US

15:00 - 15:15 Can we use cytology specimens for PD-L1 testing?
L. Bubendorf, Basel, CH

15:15 - 15:30 Comprehensive profiling of the immune microenvironment
I. Wistuba, Houston, TX/US

15:30 - 15:45 Molecular profiling
R. Büttner, Cologne, DE

15:45 - 16:15 Q&A



15:00 - 16:00	T790M: Liquid biopsy or histological samples?	Room A
15:00 - 15:10	Introduction and first vote	
15:10 - 15:30	Liquid biopsy <u>N. Reguart</u> , Barcelona, ES	
15:30 - 15:50	Histological samples <u>E. Rouleau</u> , Paris, CEDEX 5/FR	
15:50 - 16:00	Second vote and conclusions	
16:15 - 16:45	Coffee break	Hall 1
16:45 - 17:45	Poster Discussion 2	Room W
16:45 - 16:45	3PD - Co-targeting PIM1 or Src to overcome the limits of single MET inhibition <u>I. Attili</u> ¹ , N. Karachaliou ² , J. Bracht ² , J. Berenguer ² , C. Codony-Servat ² , M. Ito ³ , M. Ruge ¹ , P.F. Conte ¹ , L. Bonanno ¹ , R. Rosell ⁴ ; ¹ Padova, IT, ² Barcelona, ES, ³ Hiroshima, JP, ⁴ Badalona, Barcelona/ES	
16:45 - 16:45	51PD - Effect of MEK inhibition on PDL1 and on cytokines production profile in NSCLC cell lines and in human lymphocytes <u>F. Morgillo</u> , C.M. Della Corte, G. Viscardi, R. Di Liello, F. Papaccio, F. Ciardiello; Napoli, IT	
16:45 - 16:45	132PD - Plasma concentrations of pemetrexed to predict clinical outcomes in patients with advanced NSCLC <u>S. Visser</u> ¹ , S. Koolen ² , P. de Bruijn ² , R. Mathijssen ² , B. Stricker ² , J. Aerts ³ ; ¹ Breda, NL, ² Rotterdam, NL, ³ Rotterdam, Noord Brabant/NL	
16:45 - 16:45	52PD - EGFR clonality and tumor mutation burden (TMB) analysis based on circulating tumor DNA (ctDNA) sequencing in advanced non-small cell lung cancer (NSCLC) <u>X. Ai</u> ¹ , Y. Lin ² , A. Liu ³ , C. Xie ⁴ , X. Hu ⁵ , Q. Zhao ⁶ , Y. Zang ¹ , C. Rao ⁷ , X. Yi ⁸ , S. Lu ¹ ; ¹ Shanghai, CN, ² Shantou, CN, ³ Nanchang, CN, ⁴ Wenzhou, CN, ⁵ Nanning, CN, ⁶ Hangzhou, CN, ⁷ Ningbo, CN, ⁸ Beijing, CN	
16:45 - 16:45	133PD - Adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) for non-small cell lung cancer (NSCLC): a systematic review and meta-analysis <u>J. Raphael</u> ¹ , M. Vincent ² , G. Boldt ² , P. Shah ³ , G. Rodrigues ² , P. Blanchette ² ; ¹ Toronto, Ontario/CA, ² London, ON/CA, ³ Toronto, ON/CA	



16:45 - 18:15	Proffered Paper 2	Room B
16:45 - 17:05	<p>Multi-omics comparative analyses of pulmonary typical carcinoids, atypical carcinoids, and large-cell neuroendocrine carcinoma</p> <p><u>N. Alcala</u>¹, N. Leblay¹, D. Hervas Marin², J. McKay¹, J. Sandoval², N. Girard¹, S. Lantuejoul³, E. Brambilla³, M. Foll¹, L. Fernandez-Cuesta¹; ¹Lyon, FR, ²Valencia, ES, ³La Tronche, CEDEX 9/FR</p>	
17:05 - 17:25	<p>78O - Immune microenvironment of small-cell lung cancer (SCLC): distribution of PD-L1 expression and prognostic role of FOXP3-positive tumor infiltrating lymphocytes</p> <p><u>A. Pavan</u>, M. Fassan, M.V. Dieci, I. Attili, G. Pasello, F. Calabrese, F. Rea, M. Rugge, P.F. Conte, L. Bonanno; Padova, IT</p>	
17:25 - 17:45	<p>130O - Real-World Prevalence of PD-L1 Expression in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC): The Global, Multicentre EXPRESS Study</p> <p><u>M. Dietel</u>¹, N. Savelov², R. Salanova³, P. Micke⁴, G. Bigras⁵, T. Hida⁶, B. Piperdi⁷, T. Burke⁷, S. Khambata-Ford⁸, A. Deitz⁹; ¹Berlin, DE, ²Moscow, RU, ³Buenos Aires, AR, ⁴Uppsala, SE, ⁵Edmonton, AB/CA, ⁶Nagoya, JP, ⁷Kenilworth, NJ/US, ⁸No City Provided, NA, ⁹North Wales, US</p>	
17:45 - 18:05	<p>1O - Integration of Tissue and Circulating Parameters Identifies a Favorable Immune Profile in NSCLC Patients Treated with Nivolumab</p> <p><u>G. Mazzaschi</u>¹, F. Facchinetti¹, D. Madeddu¹, S. Buti¹, F. Gelsomino², A. Ardizzoni³, F. Aversa¹, G. Missale¹, F. Quaini¹, M. Tiseo¹; ¹Parma, IT, ²Milan, IT, ³Bologna, IT</p>	
18:05 - 18:25	<p>2O - MET activation in lung cancer up-regulates PD-L1 expression independently of JAK-STAT pathway, promoting an immunosuppressive phenotype.</p> <p><u>M. Saigi</u>¹, J.J. Albuquerque-Béjar², A. Mc Leer-Florin³, C. Pereira², E. Pros², O.A. Romero², N. Baixeras², E. Nadal¹, E. Brambilla⁴, M. Sánchez-Céspedes²; ¹Barcelona, Barcelona/ES, ²Barcelona, ES, ³Grenoble, FR, ⁴La Tronche, CEDEX 9/FR</p>	



16:45 - 18:15 How can we optimise our organisation to deliver precision oncology? Room A

16:45 - 17:05 Organisational models for biomarkers testing
S. Popat, London, GB

17:05 - 17:25 Access to personalised medicine
P. Garrido Lopez, Madrid, ES

17:25 - 17:45 The pathologist's point of view
F. Lopez-Rios, Madrid, ES

17:45 - 18:05 The patient's point of view
S. Novello, Orbassano, IT

18:05 - 18:15 Q&A

18:40 - 19:40 Industry Satellite Symposium 4 Room A

18:40 - 19:40 Industry Satellite Symposium 5 Room C

13.04.2018

08:00 - 08:50 Combining radiation with non-chemotherapy agents Room A

08:00 - 08:15 Combining radiotherapy with TKIs in oligo-progressive oncogene addicted NSCLC
N. Andratschke, Zürich, CH

08:15 - 08:30 Combining radiotherapy with immune-checkpoint inhibitors
A. Naing, Houston, TX/US

08:30 - 08:50 Discussion



08:00 - 08:50 Liquid biopsy at the initial diagnosis and during monitoring Room W

08:00 - 08:15 Which technology can we use? CTCs vs ctDNA

M. Denis, Nantes, CEDEX 1/FR

08:15 - 08:30 Diagnosis and monitoring with liquid biopsy for targeted treatment

F. Barlesi, Marseille, CEDEX 20/FR

08:30 - 08:50 Discussion

09:00 - 10:30 Immunotherapy combinations Room B

09:00 - 09:20 Immunotherapy and chemotherapy combinations

S. Ponce Aix, Madrid, ES

09:20 - 09:40 Combination of immunotherapy with targeted therapies

L. Hendriks, Maastricht, NL

09:40 - 10:00 Combination of immunotherapies

S. Antonia, Tampa, FL/US

10:00 - 10:20 Combination of immunotherapy with radiation therapy

H. Choy, Dallas, TX/US

10:20 - 10:30 Q&A



09:00 - 10:30 Mesothelioma: New roads through understanding biology Room C

09:00 - 09:20 Molecular targets: The basics
D. Fennell, Leicester, GB

09:20 - 09:40 Molecular targets: Clinical results
R. Hassan, Bethesda, US

09:40 - 10:00 Immunotherapy: The basics
J. Aerts, Rotterdam, Noord Brabant/NL

10:00 - 10:20 Immunotherapy: Clinical results
A. Scherpereel, Lille, FR

10:20 - 10:30 Q&A

09:15 - 10:15 Next generation TKI: Front line or later? Room A

09:15 - 09:25 Introduction and first vote

09:25 - 09:45 Front line
R. Califano, Manchester, GB

09:45 - 10:05 Later
E. Smit, Amsterdam, NL

10:05 - 10:15 Second vote and conclusions

10:30 - 11:00 Coffee break Hall 1



11:00 - 12:30 Proffered Paper 3 Room A

- 11:00 - 11:20 nab-Paclitaxel + Carboplatin Induction Followed by nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Results From the ABOUND.sqm Study
D. Spigel¹, R. Jotte², S. Ponce Aix³, L. Gressot⁴, M. Socinski⁵, E. Kim⁶, H. West⁷, T.J. Ong⁸, C. Gridelli⁹, M. Thomas¹⁰; ¹Nashville, US, ²Denver, US, ³Madrid, ES, ⁴Cypress, US, ⁵Orlando, US, ⁶Charlotte, US, ⁷Seattle, US, ⁸Summit, US, ⁹Avellino, IT, ¹⁰Heidelberg, DE
- 11:20 - 11:40 112O - Primary result of an investigator-initiated phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study (NCCH1505)
T. Seto¹, Y. Katsuya², H. Horinouchi², S. Umemura³, Y. Hosomi², M. Satouchi⁴, A. Kuchiba², Y. Ohe²; ¹Fukuoka, Fukuoka/JP, ²Tokyo, JP, ³Kashiwa, Chiba/JP, ⁴Akashi, JP
- 11:40 - 12:00 213O - Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study
N. Pavlakis¹, F. Grosso², N. Steele³, A. Nowak⁴, S. Novello⁵, S. Popat⁶, L. Greillier⁷, M. Reck⁸, T. Kitzing⁹, G. Scagliotti¹⁰; ¹St Leonards, NSW/AU, ²Alessandria, IT, ³Glasgow, GB, ⁴Crawley, WA/AU, ⁵Orbassano, IT, ⁶London, GB, ⁷Marseille, FR, ⁸Grosshansdorf, DE, ⁹Biberach, DE, ¹⁰Orbassano, TO/IT
- 12:00 - 12:20 214O - Multiplexed proteomics biomarkers for malignant pleural mesothelioma detection in blood
F. Cerciello¹, M. Choi², S. Sinicropi-Yao³, E. Felley-Bosco¹, R.A. Stahel¹, B. Robinson⁴, J. Creaney⁵, H. Pass⁶, O. Vitek², D. Carbone³; ¹Zürich, CH, ²Boston, US, ³Columbus, US, ⁴Sydney, AU, ⁵Nedlands, AU, ⁶New York, US

11:00 - 12:30 Resistance to TKIs Room B

- 11:00 - 11:20 General mechanisms of resistance
T. Mitsudomi, Osaka, JP
- 11:20 - 11:40 Therapeutic strategies to overcome EGFR
T.S.K. Mok, Shatin, HK
- 11:40 - 12:00 Therapeutic strategies to overcome ALK and ROS1
S. Ortiz-Cuaran, Lyon, FR
- 12:00 - 12:20 Focus on local treatment options
F. McDonald, London, GB
- 12:20 - 12:30 Q&A



11:00 - 12:30	Immune checkpoint blockade: Basic mechanisms, preclinical evaluation and mechanisms of resistance	Room C
11:00 - 11:20	Cancer immunity and immune set point <u>D. Chen</u> , South San Francisco, CA/US	
11:20 - 11:40	The basics of immunology in lung cancer <u>L. Rivoltini</u> , Milan, IT	
11:40 - 12:00	Genomic background and immune landscape <u>F. Skoulidis</u> , Houston, TX/US	
12:00 - 12:20	Mechanisms of resistance to immune checkpoint blockade <u>N. Bendriss-Vermare</u> , Lyon, FR	
12:20 - 12:30	Q&A	
12:30 - 13:00	Poster Display session	Hall 1
12:30 - 12:30	4P - Assessment of PD-L1 expression by immunohistochemistry in histological and cytological non-small cell lung carcinoma (NSCLC) in the era of immunotherapy: a national Irish study <u>A. Fabre</u> , K. Breen, J. McCormack; Dublin, IE	
12:30 - 12:30	5P - Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of non-small cell lung cancer <u>Y. Saito</u> , S. Horiuchi, H. Morooka, T. Ibi, N. Takahashi, T. Ikeya, E. Hoshi, S. Shimizu; Saitama, JP	
12:30 - 12:30	6P - Mechanisms of regulating PD-L1 expression in Non-Small Cell Lung Cancer during EMT process <u>F. Li</u> , L. Liang; Beijing, CN	
12:30 - 12:30	7P - The Regulation of FOXP3 Expression by GLI-1 in non-small Cell Lung Cancer Cells and its Influence on Lung Cancer Cell Stemness <u>H. Qi</u> ¹ , H. Jia ² , G. Chen ² ; ¹ Hong Kong, HK, ² Hong Kong, CN	
12:30 - 12:30	8P - Noncanonical Wnt11, a tumor suppressive gene by antagonizing canonical Wnt signaling, represents a putative molecularly therapeutic target in lung cancer. <u>X. Wang</u> , Shatin, HK	
12:30 - 12:30	9P - Mesenchymal stem cells' microvesicles from primary and metastatic NSCLC niches differentially modulate lung cancer cells <u>O. Attar-Schneider</u> , L. Drucker, M. Gottfried; Kfar Saba, IL	
12:30 - 12:30	10P - The Micro-Environmental Cross Talk Between Mast Cells and Lung Cancer Cells Through Cell-to-Cell Contact <u>R. Shemesh</u> ¹ , Y. Gorzalczany ¹ , N. Peled ² , R. Sagi-Eisenberg ¹ ; ¹ Tel Aviv, IL, ² Beer Sheva, IL	



- 12:30 - 12:30 11P - Glycolysis enzyme screenings identify non-glycolytic function of aldolase A that interacts and alters F-actin dynamics to promote lung cancer metastasis
Y. Chang¹, M. Hsiao²; ¹Taipei City, TW, ²Taipei, TW
- 12:30 - 12:30 12P - Cigarette smoke promotes proliferation of non-small cell lung cancer (NSCLC) via enhancing glucose uptake and glycolysis.
I. Hsieh, F. Cheng, C. Tu, C. Chen, T. Hsia, B. Wang, Y. Yeh, W. Huang; Taichung, TW
- 12:30 - 12:30 13P - The identification of binding targets for pro-metastatic protein NIFK in lung cancer
T.C. Lin, Taoyuan, TW
- 12:30 - 12:30 14P - MMP-2 1306 C/T Promoter Polymorphism and Smoking: a Possible Role as Risk Factors in Lung Cancer
A. Daniele, D. Rosa, V. Lapadula, I. Abbate, D. Galetta, E. Montagna, A. Catino; Bari, IT
- 12:30 - 12:30 15P - Comprehensive profiling of lincRNAs in lung adenocarcinoma of never smokers reveals their important roles in cancer development and prognosis
Y. Li¹, X. Zhang¹, Z. Sun²; ¹Zhengzhou, CN, ²Rochester, MN/US
- 12:30 - 12:30 16P - Long intergenic non-coding RNA 00152 promotes lung adenocarcinoma proliferation via interacting with EZH2 and repressing IL24 expression
C. Qinnan, W. Zhaoxia; Nanjing, CN
- 12:30 - 12:30 17P - Long non-coding RNA SNHG20 promotes non-small cell lung cancer cell progression by silencing of P21 expression
C. Zhenyao, C. Xin, W. Zhaoxia; Nanjing, CN
- 12:30 - 12:30 18P - The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer
W. Chenchen, W. Zhaoxia; Nanjing, CN
- 12:30 - 12:30 19P - Single Sample Predictor of Non-Small Cell Lung Cancer Histology Based on Gene Expression Analysis of Archival Tissue
A. Karlsson¹, H. Cirenajwis¹, K. Ericson-Lindqvist¹, C. Reuterswärd¹, M. Jönsson¹, A. Patthey², A. Behndig², M. Johansson², M. Planck¹, J. Staaf¹; ¹Lund, SE, ²Umea, SE
- 12:30 - 12:30 20P - ArgSS1 Expression in Squamous Cell Carcinoma of the Lung
E. Cathcart-Rake¹, A. Roden¹, A. Mansfield²; ¹Rochester, US, ²Rochester, MN/US
- 12:30 - 12:30 21P - Influence of delayed and prolonged fixation on the evaluation of immunohistochemical staining on pulmonary resection specimen.
M. Van Seijen¹, L. Brcic², A. Navarro³, I. Sansano⁴, M. Béndek⁵, B. Witte¹, I. Brcic², R. Kammler⁶, R.A. Stahel⁷, E. Thunnissen¹; ¹Amsterdam, NL, ²Graz, AT, ³Valencia, ES, ⁴Barcelona, ES, ⁵Stockholm, SE, ⁶Bern, CH, ⁷Zürich, CH
- 12:30 - 12:30 22P - Clonal and subclonal occurrence of oncogenic mutations in lung adenocarcinoma



V. Tischler¹, M. Ihle¹, A. Stenzinger², W. Weichert³, W. Jochum⁴, R. Büttner⁵, J. Wolf¹, M. Peifer¹, R. Thomas¹; ¹Köln, DE, ²Heidelberg, DE, ³München, DE, ⁴St. Gallen, CH, ⁵Cologne, DE

- 12:30 - 12:30 23P - Genomic profiling of gene aberrations in 323 Chinese NSCLC patients
Y. Liu¹, C. Xu², W. Wang³, Z. Song³, Y. Zhu⁴, Y. Guan⁵, R. Chen⁵, G. Chen³, T. Lv⁶, Y. Song⁶; ¹Shijiazhuang, CN, ²Fuzhou, CN, ³Hangzhou, CN, ⁴Jiaying, CN, ⁵Beijing, CN, ⁶Nanjing, CN
- 12:30 - 12:30 24P - Proviral Integration site for Moloney murine leukemia virus-1 (PIM-1) inhibition with AZD1208 to prevent resistance to osimertinib in EGFR mutant NSCLC
J. Bracht¹, N. Karachaliou¹, J. Berenguer¹, I. Attili², M. Ito³, C. Codony-Servat¹, J. Codony-Servat¹, M. Filipiska⁴, N. Gil⁵, R. Rosell⁶; ¹Barcelona, ES, ²Padova, IT, ³Hiroshima, JP, ⁴Gdansk, PL, ⁵Lisboa, PT, ⁶Badalona, Barcelona/ES
- 12:30 - 12:30 25P - A non pathway-specific approach in EGFR and KRAS mutant or squamous cell histology non-small cell lung cancer (NSCLC)
M. Ito¹, C. Codony-Servat², J. Codony-Servat², I. Attili³, J. Berenguer², J. Bracht², N. Gil⁴, M. Okada¹, N. Karachaliou², R. Rosell⁵; ¹Hiroshima, JP, ²Barcelona, ES, ³Padova, IT, ⁴Lisboa, PT, ⁵Badalona, Barcelona/ES
- 12:30 - 12:30 26P - Incidence of T790M mutations after progression on first Line EGFR TKIS in Advanced NSCLC: Real Time data from a tertiary cancer institute in North India.
U. Batra¹, P. Jain², P. Babu², M. Sharma²; ¹New Delhi, Rohini/IN, ²New Delhi, IN
- 12:30 - 12:30 27P - ALK immunohistochemistry scores do not predict sensitivity to crizotinib in fluorescence in situ hybridization-positive non-small cell lung cancer patients
G. Metro¹, R. Chiari², D. Giannarelli³, A. Sidoni², G. Bellezza²; ¹Perugia, (PG)/IT, ²Perugia, IT, ³Roma, IT
- 12:30 - 12:30 28P - The study of ALK rearrangement in advanced primary non-small cell lung cancer and associated metastatic lesions
C. Xu¹, W. Wang², W. Zhuang², Y. Tian², J. Zhang³, M. Fang², Y. Chen¹, G. Chen², T. Lv⁴, Y. Song⁴; ¹Fuzhou, CN, ²Hangzhou, CN, ³Taiyuan, CN, ⁴Nanjing, CN
- 12:30 - 12:30 29P - Preliminary assessment of a targeted break-point NGS assay for ALK gene fusion detection in lung adenocarcinoma samples from Chilean patients
M. Freire, R. Lizana, L. Ramos, G. Sepúlveda, A. Blanco, S. Chernilo, O. Arén, C. Fernández, R. Armisen; Santiago, CL
- 12:30 - 12:30 30P - Feasibility of anti-ROS1 SP384 for Detection of ROS1 Protein
I. Menzi¹, B. Richardson², C. Le², D. Smith², A. Hanlon Newell², C. Bell², G. Pate², R. Huang²; ¹Tucson, US, ²Tucson, AZ/US
- 12:30 - 12:30 31P - Analysis of ROS1 rearrangement non-small cell lung cancer cell blocks from pleural effusion
W. Wang¹, C. Xu², W. Zhuang¹, Y. Tian¹, J. Xu³, M. Fang¹, Y. Chen², G. Chen¹, T. Lv⁴, Y. Song⁴; ¹Hangzhou, CN, ²Fuzhou, CN, ³Hefei, CN, ⁴Nanjing, CN



- 12:30 - 12:30 32P - Serum Circulating Cell Free DNA As Potential Diagnostic And Prognostic Biomarker In Non Small Cell Lung Cancer
A. Alhanafy, S. El Shafei, M. Habib, R. Abdellatif, M. Haggag; Shebin El Kom, EG
- 12:30 - 12:30 33P - Expression of Biomarkers IDH1, CEA, TPA and CYFRA21-1 in peripheral blood and tissue of Non Small Cell Lung Carcinoma Patients detected by Real-time PCR.
A. Mishra, N. Singh, D. Sahu, S. Kumar; Lucknow, IN
- 12:30 - 12:30 34P - Recommendations for EGFR mutation testing with a fast and fully automated sample-to-result system: how to optimize DNA input instead of using lung cancer tissue?
C. Chapusot, Dijon, FR
- 12:30 - 12:30 37P - Epidemiological and Mangement of Bronchopulmonary carcinoma in Eastern Morocco about 738 Cases
I. Alloubi, K.Y. Belmokhtar, M. Bellaoui; Oujda, MA
- 12:30 - 12:30 38P - Survival of lung cancer: Bangladesh Perspective
R. Parveen¹, P. Akhtar², N. Khatun², M. Islam²; ¹Singapore, SG, ²Dhaka, BD
- 12:30 - 12:30 39P - Lung cancer in Morocco: results of a retrospective study
A. Haimier¹, F. Habib², A. Soulaymani¹, A. Mokhtari¹, H. Hami¹; ¹Kenitra, MA, ²Rabat, MA
- 12:30 - 12:30 40P - Comparison of clinical characteristics and survival of lung cancer patients in a Canadian province and in the United States according to insurance status
A. Matutino¹, E. Kornaga², M. Dean², A.A. Pereira³, G. Bebb²; ¹São Paulo, SP/BR, ²Calgary, AB/CA, ³Houston, TX/US
- 12:30 - 12:30 41P - Gender Based Variations In Presentation And Management Of Lung Cancer At A South Asian Tertiary Referral Centre
V. Vashistha¹, C. Choudhari², A. Garg², A. Gupta², G. Parthasarathy³, C. Mohan⁴, K. Madan², V. Hadda², G.C. Khilnani², A. Mohan⁴; ¹Durham, US, ²New Delhi, IN, ³Cleveland, US, ⁴Delhi, IN
- 12:30 - 12:30 42P - Is There a Delay in Diagnosis of Lung Cancer in Women?
Y. Tolwin¹, B. Silverman², N. Peled³; ¹Tel Aviv, IL, ²Jerusalem, IL, ³Beer Sheva, IL
- 12:30 - 12:30 43P - A network-based signature to predict the survival of non-smoking lung adenocarcinoma
Q. Mao, F. Jiang, L. Xu; Nanjing, CN
- 12:30 - 12:30 44P - A large population-based study on large cell neuroendocrine lung cancer: a SEER database analysis.
X. Fu, H. Zhang, Y. Yang, M. Liu, J. Lu, X. Liang, K. Nan, Y. Yao, T. Tian; Xi'an, CN
- 12:30 - 12:30 45P - Yoga as a powerful tool for smoking cessation – Convincing results of a community based randomized controlled trial
A. Aggarwal, Gurugram, IN



- 12:30 - 12:30 46P - Ban on gutka (a popular smokeless tobacco product) in India had negligible impact on smoking prevalence, large scale household survey in Delhi finds out
G. Kumar, P. Kumar; Ahmedabad, IN
- 12:30 - 12:30 48P - Clinical characteristics of Korean lung cancer patients with programmed death-ligand 1 expression
H. Park, Hwasun, KR
- 12:30 - 12:30 49P - Diagnosis of small pulmonary lesions by transbronchial lung biopsy with radial endobronchial ultrasound and virtual bronchoscopic navigation versus CT-guided transthoracic needle biopsy: a systematic review and meta-analysis
J.H. Chang, Y.J. Ryu, J.H. Lee; Seoul, KR
- 12:30 - 12:30 50P - The expression and significance of miR-146a and miR-146b in BALB/c mice pulmonary precancerous lesions induced by fine particulate matter
T. Hou, G. Wang; Beijing, CN
- 12:30 - 12:30 53P - Lung Cancer: Beyond EGFR and ALK dichotomy
C. Satheesh¹, A. Bhatt², M. Singhal³, R. Aarthi⁴, K. Shubham⁴, G. Madhura⁴, V. Maka¹, R. Naik¹, S. Iyer⁴, G. sHAFI⁴; ¹Bangalore, IN, ²Pune, IN, ³New Delhi, IN, ⁴Mumbai, IN
- 12:30 - 12:30 54P - Epidermal Growth Factor Receptor Expression (EGFR) In Serum As A Marker Of Treatment Response And Survival In Advanced Squamous Cell Lung Cancer
A. Mohan¹, A. Ansari², M. Masroor², A. Saxena², K. Luthra², R. Pandey², D. Jain², R. Kumar², G.C. Khilnani², R. Guleria²; ¹Delhi, IN, ²New Delhi, IN
- 12:30 - 12:30 56P - Plasma circulating ctDNA: Potential biomarker in non-small cell lung carcinoma and clinical significance
V. Goel¹, S. Tiwari², V. Talwar¹, N. Pattnaik³, P. Dash², S. Raina², M. John²; ¹New Delhi, Rohini/IN, ²New Delhi, IN, ³Delhi, IN
- 12:30 - 12:30 57P - Targeted sequencing of plasma-derived cfDNA in patients with metastatic NSCLC
R. Pasquale, F. Bergantino, F. Fenizia, L. Forgione, C. Roma, A. De Luca, G. Rocco, A. Morabito, N. Normanno; Napoli, IT
- 12:30 - 12:30 58P - Co-treatment of trametinib (MEK inhibitor) with TPX-0005 (Src/FAK/JAK2 inhibitor) synergistic in KRAS mutant NSCLC cell lines and CDCP1 acts as a biomarker in KRAS mutant patients (p)
C. Codony-Servat¹, M. Llanos Gil Moreno¹, J. Bracht¹, I. Attili², C. Lazzari³, V. Gregorc³, M. Ito⁴, S. Viteri¹, N. Karachaliou¹, R. Rosell⁵; ¹Barcelona, ES, ²Padova, IT, ³Milan, IT, ⁴Hiroshima, JP, ⁵Badalona, Barcelona/ES
- 12:30 - 12:30 59P - Circulating microRNAs as novel predictive markers of afatinib efficacy in squamous cell lung cancer (SCC): an exploratory sub-analysis of the LUX-Lung 8 trial
Y. Gaston Math¹, P. Fogel¹, S. Martin-Lannerée¹, C. Marcaillou¹, E. Lallet¹, N. Krämer², N. Gibson³, F. Solca⁴, E. Ehrnrooth⁵, J. Cadranet¹; ¹Paris, FR, ²München, DE, ³No City Provided, NA, ⁴Vienna, AT, ⁵Copenhagen, DK



- 12:30 - 12:30 60P - Circulating miR-31 as a predictive marker of EGFR TKI treatment efficacy in squamous cell lung cancer (SCC): a sub-analysis of the LUX-Lung 8 trial
Y. Gaston Math¹, P. Fogel¹, S. Martin-Lannerée¹, C. Marcaillou¹, E. Lallet¹, N. Krämer², N. Gibson³, F. Solca⁴, E. Ehrnrooth⁵, J. Cadranel¹; ¹Paris, FR, ²München, DE, ³No City Provided, NA, ⁴Vienna, AT, ⁵Copenhagen, DK
- 12:30 - 12:30 61P - MiR-125b plays a tumor suppressor role in inflammation-related Non-small cell lung cancer via repressing IGF-1 signal pathway
Y. Zhang, B. Han, S. Hu, Y. Lou, T. Chu, J. Qian, Q. Chang; Shanghai, CN
- 12:30 - 12:30 62P - MAP kinase signaling pathway in pulmonary adenocarcinomas: a study from India
V. Singh, P. Malik, D. Jain; New Delhi, IN
- 12:30 - 12:30 63P - Prevalence and spectrum of germline mutations among patients with familial lung cancer
M. Kanwal, Dera Ghazi Khan, Yunnan/PK
- 12:30 - 12:30 64P - Cisplatin-Resistant Phenotype: Characterization, adaptation to EGFR signaling and sensitivity to EGFR inhibitors in NSCLC cells
V. Pamidiboina¹, F. Tian², R. Kiefl², M. Schaule², R.M. Huber²; ¹Muenchen, DE, ²München, DE
- 12:30 - 12:30 65P - Fatty acid synthase (FASN) inhibition effect on EGFR TKIs sensitive and resistant cells
S. Ruiz Martínez, J. Bosch-Barrera, M. Planas, L. Feliu, R. Porta-Balanya, T. Puig; Girona, ES
- 12:30 - 12:30 66P - PALB2 mRNA Expression as a Predictive Marker in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients (p) Treated with Docetaxel-Cisplatin
N. Karachaliou¹, J. Berenguer¹, I. Chaib², J.L. Ramírez Serrano², M.T. Moran Bueno³, B. Massuti Sureda⁴, S. Calabuig Fariñas⁵, C. Camps⁵, M. Provencio Pulla⁶, R. Rosell³; ¹Barcelona, ES, ²Badalona, ES, ³Badalona, Barcelona/ES, ⁴Alicante, ES, ⁵Valencia, ES, ⁶Majadahonda, Madrid/ES
- 12:30 - 12:30 67P - The Influence of Circulating Tumor DNA Analysis on Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
R. Grinberg¹, L. Roisman¹, S. Geva², L. Soussan-Gutman³, A. Dvir³, R. Yair³, T. Twito³, R. Larman⁴, N. Peled¹; ¹Beer Sheva, IL, ²Petah Tikva, IL, ³Shoham, IL, ⁴Redwood City, CA/US
- 12:30 - 12:30 68P - In vivo study of a novel chemoablative, thermoresponsive hydrogel for intratumoural administration in a murine A549 xenograft model
S. Rossi, B. Ryan, H. Kelly; Dublin, IE
- 12:30 - 12:30 69P - The diabetes drug Canagliflozin sensitizes Non-Small Cell Lung Cancer (NSCLC) to radiotherapy and chemotherapy.
T. Tsakiridis, L. Villani, L. Broadfield, K. Marcinko, E. Tsakiridis, P. Ellis, P. Muti, G. Steinberg; Hamilton, CA
- 12:30 - 12:30 70P - Immunological efficacy of anti-tumor dendritic cell vaccine application in patients with non-small cell lung cancer
O. Gorbach, N. Khranovska, O. Skachkova, M. Inomistova, V. Sovenko, A. Ganul, V. Orel; Kiev, UA



- 12:30 - 12:30 73P - PET and neck US for the detection of cervical lymphadenopathy in patients with lung cancer and mediastinal lymphadenopathy
M. Ahmed, Galway, IE
- 12:30 - 12:30 74P - Spatial concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to 18F-FLT PET Images: A Basic Study Guided for PET-based Radiotherapy Dose Painting
C. Li, X. Meng; Jinan, CN
- 12:30 - 12:30 76P - Robustness of radiomic features in [18F]-FDG PET/CT and [18F]-FDG PET/MR
D. Vuong, M. Bogowicz, M. Huellner, P. Veit-Haibach, N. Andratschke, J. Unkelbach, M. Guckenberger, S. Tanadini-Lang; Zürich, CH
- 12:30 - 12:30 77P - Is there an incremental benefit with 68 Ga DOTA PET/CT in staging of broncho-pulmonary carcinoid tumors?
G. Karimundackal, Mumbai, IN
- 12:30 - 12:30 79P - Small cell lung cancer in the Young: Characteristics, Timeliness, and Outcome Data
S. Jiang, Y. Han, Y. Huang, X. Hao, J. Li, X. Hu, Z. Xiao, H. Wang, Y. Wang, Y. Shi; Beijing, CN
- 12:30 - 12:30 80P - Understanding the patient perspective of small cell lung cancer (SCLC)
A. Rydén¹, S. Ollis², E. Love², A. Shields², H. Jiang³, P. Dennis³; ¹Mölnådal, SE, ²Boston, MA/US, ³Gaithersburg, MD/US
- 12:30 - 12:30 81P - The influence of comorbidity on Health Utility Score (HUS) and Health-Related Quality of Life (HRQoL) in Small Cell Lung Cancer (SCLC) compared to Non-Small Cell Lung Cancer (NSCLC)
A. Vedadi, S. Shakik, M.C. Brown, W. Xu, F. Shepherd, N. Leighl, P. Bradbury, G. Liu, G. O'Kane; Toronto, CA
- 12:30 - 12:30 82P - Chemotherapy versus Combined Chemoradiotherapy: Survival Patterns among Patients with Extensive Disease Small Cell Lung Cancer
I. Uthman, M. Hassan; Ismailia, EG
- 12:30 - 12:30 83P - Radiotherapy improves the survival of patients with extensive disease small cell lung cancer: a propensity matched analysis of Surveillance, Epidemiology, and End Results database
R. Zhang, P. Li, Q. Li, Y. Qiao, T. Xu, Q. Song, Z. Fu; Wuhan, CN
- 12:30 - 12:30 84P - Patterns of Care for Patients with Small Cell Lung Cancer: A Survey of German Radiation Oncology Institutions on Recommendations for Prophylactic Cranial Irradiation
C. Eze, O. Roengvoraphoj, M. Dantes, R. Abdo, N. Schmidt-Hegemann, C. Belka, F. Manapov; Munich, DE
- 12:30 - 12:30 85P - Prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer (ES-SCLC): a tertiary cancer centre experience
A. Srivastava, K. Shelly, F. Lin; Hamilton, NZ
- 12:30 - 12:30 86P - Prophylactic Cranial Irradiation in SCLC: A Survey of German Radiation Oncology Institutions on Recommendations for Brain Imaging
C. Eze, O. Roengvoraphoj, M. Dantes, R. Abdo, N. Schmidt-Hegemann, C. Belka, F. Manapov; Munich, DE



- 12:30 - 12:30 87P - Assessment of the Prognostic Utility of the Enumeration of Circulating Tumour Cells at the End of Treatment and Disease Relapse in Small Cell Lung Cancer Patients.
A. Vickers¹, A. Xenofontos¹, L. Carter¹, R. Bernabe², M. Carter¹, L. Franklin¹, K. Morris¹, J. Pierce¹, C. Dive¹, F. Blackhall¹; ¹Manchester, GB, ²Sevilla, ES
- 12:30 - 12:30 88P - Feasibility of outpatient dinutuximab (D) and irinotecan (I) for second-line treatment of relapsed or refractory small cell lung cancer (RR SCLC): Part 1 of an open-label, randomized, Phase 2/3 study
M. Edelman¹, O. Juan², A. Navarro³, G. Golden⁴, A. Saunders⁴; ¹Philadelphia, PA/US, ²Valencia, ES, ³Barcelona, ES, ⁴Durham, US
- 12:30 - 12:30 89P - The Role of Palliative Care In Extensive Stage Lung Cancer
Y. Ahmed, Sligo, IE
- 12:30 - 12:30 90P - Study of Intestinal Flora Differences Between Small Cell Lung Cancer Patients and Healthy People
L. Zhang¹, J. Chen²; ¹Wuhan, CN, ²Dalian, CN
- 12:30 - 12:30 92P - Expression of TNFR2 in Serum Is Correlated with the Significant Risk of Subcentimeter Lung Adenocarcinoma
Y. Zhang, B. Han, B. Sun, K. Yu, T. Chu, J. Qian, Q. Chang; Shanghai, CN
- 12:30 - 12:30 93P - DNA damage repair protein expression and EGFR gene status in NSCLC
J. Wang¹, W. Luo²; ¹Chengdu, CN, ²Chongqing, CN
- 12:30 - 12:30 94P - Lung cancer recurrence in patients with pre-operative circulating tumor DNA and elevated tumor markers
S. Isaksson, A. George, M. Jönsson, H. Cirenajwis, H. Brunnström, P. Jönsson, J. Staaf, L. Saal, M. Planck; Lund, SE
- 12:30 - 12:30 95P - Intubated Versus Nonintubated General Anesthesia for Minimally Invasive VATS in Octogenarians
N. Ilic, D. Ilic, J. Juricic, D. Krnic, N. Frleta Ilic, I. Simundza, D. Orsulic; Split, HR
- 12:30 - 12:30 96P - The role of bronchial stump reinforcement by flap in prevention of broncho-pleural fistula after major lung resections
F. Caushi, I. Skenduli, A. Mezini, A. Hatibi, H. Hafizi, S. Bala, E. Hysa, F. Kokiqi; Tirana, AL
- 12:30 - 12:50 97P - Multistep prediction of cardio-pulmonary morbidity after lung cancer surgery
N. Lukavetsky, R. Litviniak, I. Hipp, T. Fetsych; Lviv, UA
- 12:50 - 12:50 98P - Trends in and Impact of Hospital-acquired Adverse Events in Patients with Lung Cancer undergoing Lung Resection
A. Gupta¹, K. Mara², K. Kernstine³, S. Khanna², D. Gerber³; ¹Dallas, US, ²Rochester, MN/US, ³Dallas, TX/US
- 12:50 - 12:50 100P - Prognostic factors in surgically resected N2 non-small cell lung cancer: Significance of the subcarinal node
R. Qiao, J. Xu, Y. Zhang, W. Yang, B. Zhang, S. Wang, R. Zhong, B. Han; Shanghai, CN



- 12:50 - 12:50 101P - Overtreatment in early lung cancer: survival in dependence of pathological confirmation
F. Zehentmayr¹, M. Sprenger², G. Fastner¹, F. Sedlmayer¹; ¹Salzburg, AT, ²Graz, AT
- 12:50 - 12:50 102P - Stereotactic lung radiotherapy for early-stage NSCLC – an institution's experience
N. Ferreira, C. Travancinha, T. Antunes, J. Fonseca, M. Labareda, F. Santos; Lisbon, PT
- 12:50 - 12:50 103P - Stereotactic body radiotherapy followed by radiofrequency ablation for inoperable stage Ib non-small cell lung cancer
H. Ding, S. Chen, T. Chen, M. Su, C. Zhu, Q. Zheng; Nanjing, CN
- 12:50 - 12:50 104P - Adjuvant chemotherapy may improve prognosis in surgically resected stage I NSCLC with lymphovascular invasion
S. Wang, J. Xu, F. Qian, W. Yang, B. Zhang, J. Qian, R. Qiao, B. Han; Shanghai, CN
- 12:50 - 12:50 105P - Feasibility study of adjuvant chemotherapy with cisplatin and pemetrexed short hydration regimen for completely resected non-small cell lung cancer
R. Dokuni¹, M. Tachihara², S. Tokunaga², K. Okuno³, M. Yamamoto¹, K. Kobayashi¹, Y. Tanaka¹, Y. Funada³, Y. Maniwa¹, Y. Nishimura²; ¹Kobe, JP, ²Kobe, Hyogo/Jp, ³Takatsuki, JP
- 12:50 - 12:50 106P - The Value of Adjuvant Chemotherapy in Patients with Resected Stage IB Solid Predominant and Solid Non-Predominant Lung Adenocarcinoma
S. Cao, J. Xu, H. Zhong; Shanghai, CN
- 12:50 - 12:50 107P - Meta analysis on defining optimal follow up of patients with early stage NSCLC after definitive therapy.
D. Wankhede, Delhi, IN
- 12:50 - 12:50 108TiP - A multi-center, prospective, randomized controlled clinical trial: comparison between wedge resection and segmentectomy in the surgical treatment of ground glass opacity-dominant stage IA non-small cell lung cancer
L. Liu, H. Liao; Chengdu, CN
- 12:50 - 12:50 113P - Exosomal miRNAs in peripheral blood as novel diagnostic biomarkers of radioresistant lung adenocarcinoma
C. Zhu¹, L. Wang¹, Q. Zhang¹, H. Xu¹, J. Tong¹, Y. Wan², Q. Zheng¹; ¹Nanjing, CN, ²University Park, PA/US
- 12:50 - 12:50 114P - Evaluation of pulmonary function parameters after moderate hypofractionated image-guided thoracic irradiation in locally-advanced node-positive non-small cell lung cancer patients with very limited lung function
F. Manapov¹, O. Roengvoraphoj¹, J. Taugner², M. Dantes¹, C. Wijaya², C. Belka¹, C. Eze¹; ¹Munich, DE, ²München, DE
- 12:50 - 12:50 115P - Heart and pulmonary artery radiation doses in non-small cell lung cancer
K. Thippu Jayaprakash, J. Rubasingham, C. Ingle, D. Muthukumar; Colchester, GB



- 12:50 - 12:50 116P - Comparison of Conformity and Homogeneity Index Values of VMAT and non-VMAT Techniques Used in Lung Cancer Radiotherapy
A. Ozen, M. Akcay, K. Duruer, O. Bozdogan, I. Surenkoc, D. Etiz; Eskisehir, TR
- 12:50 - 12:50 117P - Feasibility of moderate hypofractionated image-guided thoracic irradiation for locally-advanced node-positive non-small cell lung cancer patients with very limited lung function
F. Manapov¹, O. Roengvoraphoj¹, J. Taugner², M. Dantes¹, C. Wijaya², C. Belka¹, C. Eze¹; ¹Munich, DE, ²München, DE
- 12:50 - 12:50 118P - A Comparative Study of Sequential Chemoradiation vs Concurrent Chemoradiation vs Concurrent Chemoradiation followed by Consolidation Chemotherapy in Unresectable NSCLC
A. Datta, K. Choudhury, A. Majumdar; Kolkata, IN
- 12:50 - 12:50 119P - Cisplatin/Etoposide or Paclitaxel/Carboplatin with Concurrent Radiation Therapy in Stage IIIB Non Small Cell Lung Cancer: A One Year Phase II Trial at a Low Resource Setting
M. Shuayb, M. Shahi, M. Hossen; Dhaka, BD
- 12:50 - 12:50 120P - Optimal chemotherapy regimen for concurrent chemo-radiotherapy of locally advanced unresectable stage III non-small cell lung cancer (NSCLC)
N. Jokhadze, I. Kiladze, L. Katselashvili, M. Kacharava, N. Jankarashvili, I. Zumbadze, N. Kalandarishvili, T. Melkadze, E. Gogua; Tbilisi, GE
- 12:50 - 12:50 121P - Primary Surgery followed by Chemotherapy versus definitive concurrent Chemoradiotherapy in locally advanced non-small-cell lung cancer
I. Kiladze, V. Kuchava, N. Joxadze, L. Katselashvili, T. Melkadze; Tbilisi, GE
- 12:50 - 12:50 122P - Pathological response rates after induction radio-chemotherapy in stage III NSCLC.
F. Casas¹, D. Sanchez¹, D. Martínez¹, M. Boada¹, N. Vilariño¹, R. Martin¹, P. Paredes¹, I. Volmer¹, K.S. Cortés¹, M. Parera²; ¹Barcelona, ES, ²Vic, ES
- 12:50 - 12:50 124P - Cardiac events in stage III non-small cell lung cancer (NSCLC): an attention shift to cardio-oncology collaboration.
J. Degens¹, D. De Ruyscher¹, B. Kietselaer², A. Schols¹, A. Dingemans¹; ¹Maastricht, NL, ²Heerlen, NL
- 12:50 - 12:50 125P - Brain metastases in patients with stage N2 non-small cell lung cancer
C. Lowrie, E. McCully, S. Ansel, P. McLoone, N. Mohammed; Glasgow, GB
- 12:50 - 12:50 126TiP - SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial.
S. Rothschild¹, A. Zippelius¹, S. Savic Prince¹, M. Gonzalez², W. Weder³, A. Xyrafas⁴, C. Rusterholz⁴, M. Pless⁵; ¹Basel, CH, ²Lausanne, CH, ³Zürich, CH, ⁴Bern, CH, ⁵Winterthur, CH
- 12:50 - 12:50 127TiP - Phase I study of neo-adjuvant Stereotactic Body Radiotherapy (SBRT) in operable patients with borderline resectable locally advanced NSCLC (LA-NSCLC) (LINNEARRE I STUDY: NCT02433574).
T. Tsakiridis, N. Isfahanian, N. Nguyen, J. Wright, W. Hanna, A. Swaminath, Y. Shargal, J. Agzaraian, M. Wierzbicki, T. Chow; Hamilton, CA



- 12:50 - 12:50 145P - Impact of Next-Generation Sequencing on Survival in Lung Cancer
S. Geva¹, A. Belilovski Rozenblum¹, L. Roisman², M. Ilouze¹, E. Dudnik¹, A. Zer¹, O. Rotem¹, N. Peled²; ¹Petah Tikva, IL, ²Beer Sheva, IL
- 12:50 - 12:50 146P - The Clinical Impact of Comprehensive cfDNA Genomic Testing in Lung Cancer
S. Geva¹, A. Belilovski Rozenblum¹, R. Grinberg², A. Dvir³, L. Soussan-Gutman³, L. Roisman², E. Dudnik¹, A. Zer¹, O. Rotem¹, N. Peled²; ¹Petah Tikva, IL, ²Beer Sheva, IL, ³Shoham, IL
- 12:50 - 12:50 147P - Clinical Testing of ctDNA from NSCLC Patients Using A 17-Gene Liquid Biopsy Mutation Panel
D. Eberhard, J. Bennett, D. Davison, C. Hammond, A. Petty, J. Pluenneke, A. Dei Rossi, G. Alexander, D. Paragas, M. Lopatin; Redwood City, CA/US
- 12:50 - 12:50 148P - Method comparison for detection of epidermal growth factor receptor (EGFR) T790M mutation in matched biopsied tumour sections and plasma samples
J. Longshore¹, S. Patel², B. Collins², M. Cantarini³, S. Jenkins⁴; ¹Charlotte, US, ²Cambridge, GB, ³Macclesfield, Cheshire/GB, ⁴Macclesfield, GB
- 12:50 - 12:50 149P - Real-world outcomes with first-line afatinib in EGFR mutant NSCLC adenocarcinoma - a single centre experience exploring effects of dose-reduction
N. Tokaca¹, M. O'Brien¹, J. Bhosle², N. Yousaf¹, R. Kumar², S. Popat¹, D. Walder²; ¹London, GB, ²Sutton, GB
- 12:50 - 12:50 150P - Correlation between erlotinib-induced rash and efficacy in first-line therapy of patients with advanced non-small cell lung cancer (NSCLC) expressing epidermal growth factor receptor (EGFR)-mutation: A prospective, multi-center, open-label, single-arm, phase II study
M. Gottfried¹, S. Keren Rosenberg², J. Dudnik³, M. Wollner², J. Bar⁴, A. Onn⁴, O. Frenkel⁵, N. Maimon⁶; ¹Kfar Saba, IL, ²Haifa, IL, ³Beer Sheva, IL, ⁴Ramat Gan, IL, ⁵Hod Hasharon, IL, ⁶Rishon Le Zion, IL
- 12:50 - 12:50 151P - Maintenance therapy using Tyrosine Kinase Inhibitor (Erlotinib) or Pemetrexed in Metastatic/Locally Advanced in EGFR Mutation-negative Lung cancer: Comparison of results
K. Gupta, A. Joshi, V. Noronha, S. Parthiban, V. Patil, A. Janu, R. Kaushal, K. Prabhaskar; Mumbai, IN
- 12:50 - 12:50 152P - Impaired liver function was associated with PFS of EGFR TKI treatment
Q. Zhu, Y. Chen, Y. Hong, Z. Ding; Chengdu, CN
- 12:50 - 12:50 153P - EGFR T790M co-exists with sensitive mutations in the same cell group in lung adenocarcinoma patients
X. Shi, S. Wu, H. Wang, Z. Liang, X. Zeng; Beijing, CN
- 12:50 - 12:50 154P - CNS response to osimertinib in patients with EGFR mutated lung adenocarcinoma: real world data
R. Devjak¹, N. Turnsek Hitij², K. Mohorcic², M. Rajer², T. Cufer²; ¹Ljubljana, SI, ²Golnik, SI
- 12:50 - 12:50 155P - Antitumoral efficacy of dual blockade of EGFR signaling by osimertinib in combination with selumetinib or cetuximab in activated EGFR human NSCLC tumor models



F. Morgillo¹, C.M. Della Corte¹, R. Alfieri², P. Petronini², S. La Monica², F. Papaccio¹, F. Ciardiello¹; ¹Napoli, IT, ²Parma, IT

- 12:50 - 12:50 156P - ASTRIS, a real-world study with osimertinib in patients with non-small cell lung cancer (NSCLC) EGFR T790M mutated: Characteristics and diagnostic methods used for patients included in Spain
D. Vicente Baz¹, A. Paredes Lario², M.T. Moran Bueno³, B. Massuti Sureda⁴, N. Reguard⁵, R. Álvarez⁶, A. Insa Molla⁷, O. Juan⁸, G. Marquez⁹, M. Provencio Pulla¹⁰; ¹Sevilla, ES, ²San Sebastian, ES, ³Badalona, Barcelona/ES, ⁴Alicante, ES, ⁵Barcelona, ES, ⁶Madrid, ES, ⁷Valencia, Valencia/ES, ⁸Valencia, ES, ⁹Ciudad De Buenos Aires, AR, ¹⁰Majadahonda, Madrid/ES
- 12:50 - 12:50 157P - Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: a Phase IV study
S. Thongprasert¹, S. Geater², D. Clement³, A. Abdelaziz⁴, J. Reyer-Igama⁵, D. Jovanovic⁶, S. Suresh⁷, A. Cseh⁸, R. Gaafar⁹; ¹Maidenhead, GB, ²Songkla, TH, ³Iasi, RO, ⁴Alexandria, EG, ⁵Baguio City, PH, ⁶Belgrade, RS, ⁷Singapore, SG, ⁸Vienna, AT, ⁹Cairo, EG
- 12:50 - 12:50 158P - Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: overview of clinical data
A. Märten¹, N. Yamamoto², C. Yu³, S. Ou⁴, C. Zhou⁵, Y. Wu⁶; ¹Ingelheim Am Rhein, DE, ²Wakayama, JP, ³Taipei, TW, ⁴Orange, CA/US, ⁵Shanghai, CN, ⁶Guangzhou, CN
- 12:50 - 12:50 159P - Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: a Spanish retrospective multicentre study
M.T. Moran Bueno¹, C. Aguado², M. Dómine², A. Gomez Rueda², A. Calles², S.M. Cedres³, N. Viñolas³, D. Isla⁴, R. Palmero⁵, M. Sereno Moyano²; ¹Badalona, Barcelona/ES, ²Madrid, ES, ³Barcelona, ES, ⁴Zaragoza, ES, ⁵L'hospitalet De Llobregat, Barcelona, ES
- 12:50 - 12:50 160P - Real world study of lung squamous cell carcinoma patients with EGFR mutation treated with EGFR-TKI
L. Miao¹, G. Lin², Y. Wu³, J. Chen⁴, X. Ai⁵, M. Yuan⁶, R. Chen⁶; ¹Nanjing, CN, ²Fuzhou, CN, ³Dongguan, CN, ⁴Changsha, CN, ⁵Shanghai, CN, ⁶Beijing, CN
- 12:50 - 12:50 161P - The survival of advanced non small cell lung cancer with Epidermal Growth Factor Receptor in Thailand, A single institution review
A. Supavavej, M. Tandhansakul; Bangkok, TH
- 12:50 - 12:50 162P - Responses to EGFR TKIs and ALK TKIs in advanced NSCLC patients harboring concomitant EGFR and ALK alterations
S. Wang, T. Chu, B. Zhang, B. Han, B. Yan, R. Qiao; Shanghai, CN
- 12:50 - 12:50 163P - The influence of 2nd and 3rd generation TKI in EGFR mt+ and ALK+ patients on OS and PFS: Results of the NOWEL network
J. Roeper¹, M. Netchaeva², A. Lueers³, M. Falk⁴, M. Tiemann¹, C. Wesseler⁵, G. Wiest⁵, S. Sackmann², D. Ukena², F. Griesinger³; ¹Berlin, DE, ²Bremen, DE, ³Oldenburg, DE, ⁴Hamburg, Hamburg/DE, ⁵Hamburg, DE



- 12:50 - 12:50 164P - Feasibility of Liquid Biopsy Using Plasma and Platelets for Detection of ALK Rearrangements in Non-Small Cell Lung Cancer
C. Park¹, H. Park¹, H. Cho¹, Y. Choi², I. Oh¹, Y. Kim¹; ¹Hwasun, KR, ²Gwangju, KR
- 12:50 - 12:50 165P - Analysis of our experience of ROS-1 patients in Advanced NSCLC
N. Pande, A. Joshi, V. Noronha, V. Patil, A. Mahajan, K. Prabhash; Mumbai, IN
- 12:50 - 12:50 166P - Evidence-based conclusions and inclinations of pemetrexed, taxane and bevacizumab in advanced lung cancer
S. Shaheen¹, L. Ji², J. Morgan², S. Otoukesh², H. Mirshahidi²; ¹Loma Linda, US, ²Loma Linda, CA/US
- 12:50 - 12:50 167P - Efficacy of Pemetrexed-Based Chemotherapy in Advanced Lung Adenocarcinoma Patients with ROS-1 Rearrangement
B. Zhang, T. Chu, J. Xu, Y. Zhang, B. Yan, Y. Dong, J. Qian, R. Qiao, S. Wang, B. Han; Shanghai, CN
- 12:50 - 12:50 168P - Pemetrexed dosing regimens in patients with advanced NSCLC
S. Visser¹, S. Koolen², P. de Bruijn², B. Stricker², R. Mathijssen², J. Aerts³; ¹Breda, NL, ²Rotterdam, NL, ³Rotterdam, Noord Brabant/NL
- 12:50 - 12:50 169P - Nephrotoxicity of pemetrexed maintenance in patients with advanced NSCLC: Two cohort studies
S. Visser¹, J. Huisbrink², N. Van 'T Veer¹, J. Van Toor², T. Van Boxem³, N. Van Walree¹, B. Stricker², J. Aerts⁴; ¹Breda, NL, ²Rotterdam, NL, ³Roosendaal, NL, ⁴Rotterdam, Noord Brabant/NL
- 12:50 - 12:50 170P - A Phase II Trial of Nab-Paclitaxel and Gemcitabine in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum Based Chemotherapy
Y. Hatakeyama¹, M. Tachihara², T. Kiri², A. Hata², T. Nagano², M. Yamamoto², K. Kobayashi², H. Ohnishi¹, N. Katakami², Y. Nishimura²; ¹Akashi, JP, ²Kobe, JP
- 12:50 - 12:50 171P - A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer
Y. Kono¹, Y. Hattori¹, K. Nishino², R. Uozumi³, S. Itoh¹, T. Inoue², T. Kumagai², S. Morita³, F. Imamura², M. Satouchi¹; ¹Akashi, JP, ²Osaka, JP, ³Kyoto, JP
- 12:50 - 12:50 172P - Safety and Efficacy Phase 2 Study of nab-Paclitaxel Maintenance Treatment after nab-Paclitaxel plus Carboplatin in Stage IIIB/IV Non-small Cell Lung Cancer.
A. Nakao¹, J. Uchino², N. Nagata¹, K. Takayama², K. Watanabe¹, M. Fujita¹; ¹Fukuoka, JP, ²Kyoto, JP
- 12:50 - 12:50 173P - Apatinib plus S-1 shows encouraging response in advanced Non-small-Cell Lung Cancer as laterline chemotherapy.
Z. wu, J. Wu; Beijing, CN
- 12:50 - 12:50 174P - Aprepitant, palonosetron and dexamethasone proved effective to prevent chemotherapy-related nausea and vomiting in lung cancer
Y. Zhang, N. Yang, F. Zeng, F. Wu; Changsha, CN



- 12:50 - 12:50 175P - A prospective, randomized, double-blind study of pre-chemotherapy hydration with or without mannitol to prevent renal toxicity in non-small cell lung cancer (NSCLC) patients receiving cisplatin-gemcitabine chemotherapy:
N. Thavornpattanpong, Songkla, TH
- 12:50 - 12:50 176P - PrediCare: a New Diagnostic Tool Predicting Imminent Disease Progression in Advanced NSCLC Patients by Machine-Learning Integration of Three Serum Biomarkers
Y. Kogan¹, M. Kleiman¹, S. Shannon¹, M. Elishmereni¹, E. Taub¹, L. Aptekar², R. Brenner³, R. Berger⁴, H. Nechushtan², Z. Agur¹; ¹Bene Ataroth, IL, ²Jerusalem, IL, ³Holon, IL, ⁴Ramat Gan, IL
- 12:50 - 12:50 177P - Clinicopathologic characteristics in Large Cell Neuroendocrine Carcinomas of the Lung (LCNCL).The experience of one center.
M. Vaslamatzis¹, A. Laskarakis², T. Tegos¹, M. Pavlakis¹, T. Argyrakos¹, N. Alevizopoulos¹, C. Zoublios¹, E. Vasili¹, E. Gioti¹, K. Athanasiadi¹; ¹Athens, GR, ²Piraeus, GR
- 12:50 - 12:50 178P - Smo inhibitor LDE225 reverses epithelial-mesenchymal transition (EMT) in non-small cell lung cancer(NSCLC) cells
Y. Yu, Y. Cao, B. Pan, S. Jin; Harbin, CN
- 12:50 - 12:50 179P - The cytoplasmic LKB1 promotes the growth of human lung adenocarcinoma by enhancing autophagy
M.J. Liu, L. Jiang, X. Fu, X. Liang; Xi'an, CN
- 12:50 - 12:50 180P - Significant Progress in Palliative Treatment of NSCLC over the last Decades – Correlation of Treatment Milestones with Survival in Unselected Patients
S. Rothschild¹, R. Nachbur¹, N. Herzog¹, J. Passweg¹, M. Pless²; ¹Basel, CH, ²Winterthur, CH
- 12:50 - 12:50 181P - Real-World Comparative Effectiveness of Treatment Sequences in Metastatic Non-Small Cell Lung Cancer with Squamous Histology
H. Yang¹, B. Levy², J. Signorovitch³, O. Patterson-Lomba³, C. Xiang³, M. Parisi⁴; ¹Boston, US, ²Washington, DC/US, ³Boston, MA/US, ⁴Summit, NJ/US
- 12:50 - 12:50 182P - Real world anti-PD-L1 treatment (tx) outcomes in a multinational European non-small cell lung cancer (NSCLC) cohort with focus on toxicity (tox) and brain metastases (BM): Preliminary data from an EORTC young investigators lung cancer group collaborative analysis
R. Tassi¹, F. Taylor², S. Canova³, L. Low⁴, O. Abdel-Rahman⁵, B. Hasan⁶, E. De Maio⁶, A. Levy⁷, B. Besse⁸, L. Hendriks⁹; ¹Firenze, IT, ²Sheffield, S. Yorks/GB, ³Monza, IT, ⁴Sheffield, GB, ⁵Cairo, EG, ⁶Brussels, BE, ⁷Villejuif, FR, ⁸Villejuif, CEDEX/FR, ⁹Maastricht, NL
- 12:50 - 12:50 183P - Progression of central nervous system metastases in advanced non-small cell lung cancer patients effectively treated with first-generation EGFR-TKI
M. Yu, Q. Zhao, Y. Li, S. Zhang, X. Zhou, J. Wang, Y. Wang, Y. Lu, Y. Liu; Chengdu, CN
- 12:50 - 12:50 184P - Clinico-radiological pattern of response to nivolumab in stage IV NSCL: a real life experience over two years.
M. Perna, V. Scotti, C. Muntoni, C. Moroni, F. Giannelli, D. Cozzi, F. Mazzoni, V. Bonti, D. Lavacchi, L. Livi; Firenze, IT



- 12:50 - 12:50 185P - Retrospective study of tumour responses and toxicities associated with anti- PD1 antibody therapy in elderly cancer patients(>75yo) in comparison to patients ≤ 75yo with metastatic non small cell lung cancer
L.C. CHONG¹, N. Corsini², J. Hogan-Doran², M. Brown²; ¹Adelaide, AU, ²Adelaide, SA/AU
- 12:50 - 12:50 186P - Thyroid Toxicity as an Immune-related Adverse Event in Patients with Non-Small Cell Lung Cancer During Treatment with Immune Checkpoint Inhibitors
K. Syrigos, A. Charpidou, A. Asimakopoulou, I. Vathiotis, I. Gkiozos, S. Tsagouli, P. Boura, D. Grapsa, E. Kotteas; Athens, GR
- 12:50 - 12:50 187P - Nivolumab-related immune-related adverse events in advanced NSCLC predict therapeutic objective response
J. Rogado¹, V. Pacheco Barcia¹, B. Vera¹, P. Toquero¹, R. Mondejar², A.I. Ballesteros Garcia¹, O. Donnay¹, N. Romero Laorden³, R. Colomer Bosch¹, J.M. Sánchez-Torres¹; ¹Madrid, ES, ²Cuenca, ES, ³Madrid, Madrid/ES
- 12:50 - 12:50 188P - Treatment switching—adjusted overall survival (OS) in KEYNOTE-024: first-line pembrolizumab versus chemotherapy in patients with advanced non–small-cell lung cancer (NSCLC)
M. Reck¹, D. Rodríguez-Abreu², A. Robinson³, R. Hui⁴, T. Csósz⁵, K. Vandormael⁶, W. Malbecq⁶, M..C. Pietanza⁷, J. Brahmer⁸; ¹Grosshansdorf, DE, ²Las Palmas, ES, ³Kingston, ON/CA, ⁴Westmead, NSW/AU, ⁵Szolnok, HU, ⁶Brussels, BE, ⁷Kenilworth, NJ/US, ⁸Baltimore, MD/US
- 12:50 - 12:50 189P - Are pretreatment neutrophil-lymphocyte ratio (NLR) , platelet-lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI) levels useful in predicting the outcomes of patients with advanced nonsmall-cell lung cancer?
B. Komurcuoglu¹, A. Evkan², G. Karakurt²; ¹Izmir, Karsiyaka/TR, ²Izmir, TR
- 12:50 - 12:50 190P - Are neutrophil-to-lymphocyte ratio (NLR) and neutrophil count percentage (NCP) predictors of Nivolumab outcome and toxicity in NSCLC?
J. Rogado¹, V. Pacheco Barcia¹, P. Toquero¹, B. Vera¹, R. Mondejar², N. Romero Laorden³, A.I. Ballesteros Garcia¹, O. Donnay¹, R. Colomer Bosch¹, J.M. Sánchez-Torres¹; ¹Madrid, ES, ²Cuenca, ES, ³Madrid, Madrid/ES
- 12:50 - 12:50 192P - KRAS as predictive biomarker of response to checkpoint inhibitors in NSCLC
A. Addeo, J. Torralvo, P. Dietrich; Geneva, CH
- 12:50 - 12:50 193TiP - Phase 3 Study of Epacadostat Plus Pembrolizumab With or Without Platinum-based Chemotherapy vs Pembrolizumab Plus Chemotherapy For First-Line Metastatic Non-Small Cell Lung Cancer (mNSCLC): ECHO-306/KEYNOTE-715
M. Garassino¹, S. Rubin², Y. Zhao², Y. Luo³, A. Samkari³, R. Hui⁴; ¹Milan, IT, ²Wilmington, DE/US, ³Kenilworth, NJ/US, ⁴Westmead, NSW/AU
- 12:50 - 12:50 194TiP - eXalt3: Phase 3 Randomized Study Comparing Ensartinib to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients
L. Horn¹, Y. Wu², M. Reck³, C. Liang⁴, F. Tan⁵, K. Harrow⁴, V. Oertel⁴, G. Dukart⁴, T.S.K. Mok⁶; ¹Nashville, TN/US, ²Guangzhou, CN, ³Grosshansdorf, DE, ⁴Palm Beach Gardens, FL/US, ⁵Beijing, CN, ⁶Shatin, HK



- 12:50 - 12:50 195TiP - A Phase 3, Randomized, Double-Blind Study of Epacadostat Plus Pembrolizumab vs Pembrolizumab as First-Line Therapy for Metastatic Non-Small Cell Lung Cancer (mNSCLC) Expressing High PD-L1 Levels (ECHO-305/KEYNOTE-654)
L. Paz-Ares¹, S. Rubin², Y. Zhao², L. Xu³, A. Samkari³, M. Awad⁴; ¹Madrid, ES, ²Wilmington, DE/US, ³Kenilworth, NJ/US, ⁴Boston, US
- 12:50 - 12:50 196TiP - CheckMate 384: A Phase 3b/4 Dose-Frequency Optimization Trial of Nivolumab in Advanced or Metastatic NSCLC
E. Garon¹, N. Reinmuth², R. Harris³, P. Mitchell⁴, J. Zhu⁵, G. Selvaggi⁶, S. Agrawal⁷, E. Pichon⁸; ¹Santa Monica, CA/US, ²Gauting, DE, ³Johnson City, NY/US, ⁴Melbourne, VIC/AU, ⁵Princeton, NJ/US, ⁶New York, NJ/US, ⁷Princeton, US, ⁸Tours, CEDEX 9/FR
- 12:50 - 12:50 197TiP - A Phase 1/2 trial of Selinexor combined with Docetaxel for Previously Treated, Advanced KRAS Mutant Non-small Cell Lung Cancer
A. Gupta¹, H. West², D.R. Camidge³, T. Stinchcombe⁴, L. Horn⁵, J. Saltarski¹, J. Bolluyt⁶, M. White⁶, D. Gerber⁶; ¹Dallas, US, ²Seattle, WA/US, ³Denver, CO/US, ⁴Durham, NC/US, ⁵Nashville, TN/US, ⁶Dallas, TX/US
- 12:50 - 12:50 198TiP - Afatinib plus EGF Pathway Targeting Immunization (EGF-PTI) as 1st line therapy for EGFR mutant NSCLC: the EPICAL study
N. Karachaliou¹, A. Cardona Zorrilla², D. Rodríguez-Abreu³, M. Cobo Dols⁴, N. Reguart Aransay¹, S. Viteri¹, J. Codony-Servat¹, M.A. Molina-Vila¹, E. D'Hondt⁵, R. Rosell⁶; ¹Barcelona, ES, ²Bogotá, CO, ³Las Palmas, ES, ⁴No City Provided, NA, ⁵Kruikebe, BE, ⁶Badalona, Barcelona/ES
- 12:50 - 12:50 199TiP - TTFIELDS concurrent with standard of care for stage 4 non-small cell lung cancer (NSCLC) following platinum failure: Phase 3 LUNAR study
U. Weinberg¹, O. Farber², M. Giladi², Z. Bomzon², E. Kirson²; ¹Luzern, CH, ²Haifa, IL
- 12:50 - 12:50 201P - Isolation of Circulating Tumor Cells and Potential Heterogeneity Analysis in Advanced Non-Small Cell Lung Cancer
H. Zhang, Q. Zhang, J. Nong, J. Wang, Z. Yan, L. Yi, X. Cheng, Z. Liu, S. Zhang; Beijing, CN
- 12:50 - 12:50 202P - The clone evolutionary landscape and genomic characteristics of osteosarcoma and lung metastasis
J. Lai¹, C. Xu¹, W. Wang², Z. Song², Y. Chen¹, Y. Zhu³, S. Cai⁴, G. Chen², T. Lv⁵, Y. Song⁵; ¹Fuzhou, CN, ²Hangzhou, CN, ³Jiaxing, CN, ⁴Shanghai, CN, ⁵Nanjing, CN
- 12:50 - 12:50 203P - Combined Pulmonary Metastasectomy and Chemotherapy in Patients with Colorectal Lung Metastases and Concurrent Extrapulmonary Disease
M. Faisal, I. Uthman, A. Abo Bakr; Ismailia, EG
- 12:50 - 12:50 204P - Clinicopathological Features, Treatment patterns and outcomes of Pulmonary Metastasectomy
P. Shivanna, S. Deo, N.K. Shukla, S. Bhorival, R. Thakur, S. Bakshi, R. Palaniappan, S. Kumar; New Delhi, IN



- 12:50 - 12:50 205P - RNA-seq analysis of lung adenocarcinomas reveals different circular RNA expression profiles between Non-metastatic and Metastatic patients
D. Wu¹, X. Qi¹, B. Qin²; ¹Xiamen, CN, ²Beijing, CN
- 12:50 - 12:50 206P - Isolated splenic metastasis from non-small cell lung cancer: Study of an extremely rare clinical entity with review of all cases reported in the literature
N. Mitsimponas¹, M. Mitsogianni², A. Giagounidis²; ¹Athens, GR, ²Düsseldorf, DE
- 12:50 - 12:50 207P - A comparison of outcomes of stereotactic body radiotherapy versus metastasectomy in patients with pulmonary metastases
Y.H. Lee¹, K.M. Kang¹, H. Choi¹, I.B. Ha¹, H. Jeong¹, J.H. Song², B.K. Jeong¹; ¹Jinju, KR, ²Changwon, KR
- 12:50 - 12:50 208P - Metastatic non-small cell lung carcinoma: About 420 cases
H. Loubna, Fez, MA
- 12:50 - 12:50 209P - The management of brain disease (BD) in ALK-rearranged non-small cell lung cancer (ALK NSCLC): Can systemic treatment delay the initiation of local treatments? Experience of the Ramón y Cajal University Hospital (RyCUH, Madrid)
R. Martín Huertas, I. Ciscar Garcia, C. Saavedra Serrano, J.J. Serrano Domingo, E. Corral de la Fuente, J.J. Soto Castillo, A. Gomez Rueda, M.E. Olmedo Garcia, P. Garrido Lopez; Madrid, ES
- 12:50 - 12:50 210P - Brain Oligometastases in NSCLC: Therapeutic Effect and Prognostic Factors of WBRT combined with Intracarotid Infusion of Elemenene
Y. XU, X. Lv, Y. Liu, B. Dong; Dalian, CN
- 12:50 - 12:50 211P - First Analysis of a Real World Study to Explore the Character and Treatment Outcome of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) on Non Small Cell Lung Cancer(NSCLC) with Brain Metastases(BM)
H. Zhang¹, L. Liu¹, C. Zhang², N. Zhang¹, H. Su¹, Y. Song¹, J. Min¹; ¹Xi'an, CN, ²Beijing, CN
- 12:50 - 12:50 212P - Clinical Experience and predictive factors of response to Whole Brain radiotherapy in metastatic lung cancer – A Single Institute experience
V. Pareek, R. Bhalavat, M. Chandra; Mumbai, IN
- 12:50 - 12:50 217P - Impact of VEGF and CD74 Expression on Response and Survival of Malignant Pleural Mesothelioma Patients Treated with Gemcitabine and Cisplatin; a phase II retrospective study
D. Soliman, M.A. Ellithy, A. Saad, M. Jassim, H. Abou Gabal, W. Osman; Cairo, EG
- 12:50 - 12:50 218P - Platinum-based Pemetrexed versus Platinum-based Gemcitabine for the Treatment of Patients with Malignant Pleural Mesothelioma: An Institutional Experience
S. Shahin, A. Saad, R. Ghali; Cairo, EG
- 12:50 - 12:50 219P - Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)
S. Cedres, F. Amair, A. Martinez-Marti, A. Navarro, N. Pardo, J. Remon-Masip, J.M. Miquel, G. Villacampa, R. Dienstmann, E. Felip Font; Barcelona, ES



- 12:50 - 12:50 220P - Effects of pifithrin- μ on the growth of acidity-tolerant malignant mesothelioma cells and epithelial-mesenchymal transition
S. Lee, Y. Lee; Cheonan, KR
- 12:50 - 12:50 221P - Treatment experience of Pleural Malignant Mesothelioma in a tertiary referral center in Mexico
A. Gutierrez¹, G. Nuñez-Cerrillo¹, Y.A. Remolina-Bonilla¹, A. Armengol-Alonso², R. Trejo-Rosales²; ¹Mexico City, MX, ²Ciudad De México, MX
- 12:50 - 12:50 222P - Women: the other face of malignant pleural mesothelioma
M. Brandão, M. Rocha, J. Silva, L. Nascimento, T. Gomes, B. Conde, A. Fernandes; Vila Real, PT
- 12:50 - 12:50 223P - Sarcomatoid lung carcinoma: An Uncommon and Deadly Entity
A. Sharma¹, E. Contreras², K. Sandoval², L. Nicholson³, J. Waalen³, M. Bhangoo³; ¹La Jolla, US, ²San Diego, CA/US, ³La Jolla, CA/US
- 12:50 - 12:50 224P - The role of surgery in the treatment of lung neuroendocrine tumors (NETs) based on a 3-years experience of a thoracic department
B. von Amann, C. Rodrigues, A. Ribeiro, C. Bárbara, F. Félix; Lisbon, PT
- 12:50 - 12:50 225P - Surgical experience of advanced Bronchopulmonary Carcinoids: an analysis from tertiary care hospital of North India
N. Kumar¹, S. Deo¹, N. Shukla¹, S. Boriwal¹, V. Kumar¹, P. Ramanathan¹, D. Jain², K. Madan², S. Kumar¹; ¹Delhi, IN, ²New Delhi, IN
- 12:50 - 12:50 226P - Accuracy of mutation analysis in small tissues from transbronchial lung biopsy with radial probe endobronchial ultrasound
M.K. Lee, J.S. Eom; Busan, KR
- 12:50 - 12:50 227P - Stereotactic Body Radiotherapy with Helical TomoTherapy for lung tumors: a single-center experience.
V. Figlia, F. Cuccia, V. Valenti, A. Tripoli, G. Terranova, A. Lo Casto, G. Failla, T. Cucchiara, G. Mortellaro, G. Ferrera; Palermo, IT
- 12:50 - 12:50 228P - Augmentation of NAD⁺ by NQO1 activation attenuates cisplatin-mediated hearing impairment
S. Yang, K.K. Kwon, H. So; Iksan, KR
- 12:50 - 12:50 229P - Clinical and Laboratory Markers of Prognosis in Lung Cancer Patients with Hypercalcemia
K. Syrigos, A. Ntineri, P. Bakakos, D. Grapsa, E. Dalakou, E. Kotteas, A. Charpidou; Athens, GR
- 12:50 - 12:50 230P - Experience with the implant of vascular access devices by medical oncologist in a non-surgical scenery
A. Revuelta, D. Rodríguez Rubí, L. Fález, M.D.P. Solís, S. Fernández Arrojo, C. Iglesias Gómez, D. Gómez, J. del Río Fernández, A. Castillo Trujillo, E. Esteban González; Oviedo, ES
- 12:50 - 12:50 231P - Impact of the continuity of nursing care delivered by a pivot nurse in oncology on improving satisfaction and quality of life of patients with advanced lung cancer
E. Kassouf¹, M. Tehfe², M. Floresci², N. Blais²; ¹St-Charles-borromée, Quebec/CA, ²Montreal, QC/CA



- 12:50 - 12:50 232TiP - Lanreotide autogel/depot in lung neuroendocrine tumours: the randomized, double-blind, placebo-controlled, international phase 3 SPINET Study
X. Truong¹, D. Reidy-Lagunes², M. Kulke³, E. Wolin², S. Singh⁴, D. Ferone⁵, D. Hoersch⁶, A. Houchard¹, M. Caplin⁷, E. Baudin⁸; ¹Boulogne-Billancourt, FR, ²New York, US, ³Boston, MA/US, ⁴Toronto, Ontario/CA, ⁵Genova, IT, ⁶Bad Berka, DE, ⁷London, GB, ⁸Villejuif, FR
- 13:00 - 14:00 Industry Satellite Symposium 6 Room A
- 13:00 - 14:00 Industry Satellite Symposium 7 Room C
- 14:10 - 14:40 Keynote lecture Room B
- 14:10 - 14:40 Predictive biomarkers for immune checkpoints inhibitors
O. Michielin, Lausanne, CH



14:45 - 15:45 Poster Discussion 3 Room W

- 14:45 - 14:45 35PD - Magnitude of exposure to biomass fuel smoke and risk of lung cancer in women. Cases and controls study.
R. Baez-Saldana¹, U. Rumbo-Nava², A. Canseco-Raymundo², P. Castillo-Gonzalez², S. Leon-Duenas², R. Rivera-Rosales², C. Luna-Rivero²; ¹Ciudad De México, MX, ²Mexico City, MX
- 14:45 - 14:45 36PD - New Demographic Characteristics of Lung Cancer Patients in East Asia? Practice of Low-dose Spiral Computed Tomography Screening in Shanghai Major Hospitals
X. Luo, Shanghai, CN
- 14:45 - 14:45 71PD - Emergency Department Incidental Lung Nodule Follow Up: A Best Practice Initiative
K.A. Lee, Jupiter, US
- 14:45 - 14:45 72PD - MR Imaging Radiomics of NSCLC Brain metastases: A Potential Targetable Imaging Biomarker for EGFR status.
A. Mahajan, K. Prabhash, A. Ghaytidak, V. Noronah, A. Joshi, V. Patil; Mumbai, IN
- 14:45 - 14:45 200PD - High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: a case series in a tertiary cancer center
C. Fahim, J. Agzarian, W. Hanna, R. Juergens, Y. Shargall, M. Simunovic; Hamilton, CA
- 14:45 - 14:45 215PD - Survival Patterns in Patients with Malignant Pleural Mesothelioma Using Multimodality Therapy
M. Hassan, I. Uthman; Ismailia, EG
- 14:45 - 14:45 216PD - Should radical surgery be performed in non-epithelioid malignant pleural mesothelioma?
L. Lang-Lazdunski, N. Tokaca, K.R. Lal, J. Steele, T. Newsom-Davis, D. Landau, J. Spicer, S. Popat; London, GB



14:45 - 16:15 ESMO-IASLC Best Abstracts Room B

- 14:45 - 15:05 910 - Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas following Complete Lobectomy: What Does An Analysis Based on Recurrence Risk Stratification Tell Us
J. Qian, J. Xu, S. Wang, F. Qian, W. Yang, B. Zhang, Y. Zhang, X. Zhang, B. Han; Shanghai, CN
- 15:05 - 15:25 1090 - Health-related Quality of Life (QoL) after Prophylactic Cranial Irradiation (PCI) vs no PCI for stage III NSCLC patients: results from the NVALT-11/DLCRG-02 study
W. Witlox¹, B. Ramaekers¹, H. Groen², A. Dingemans¹, J. Praag³, J. Belderbos⁴, V. Van Der Noort⁴, H. Van Tinteren⁴, M. Joore¹, D. De Ruyscher¹; ¹Maastricht, NL, ²Groningen, NL, ³Rotterdam, NL, ⁴Amsterdam, NL
- 15:25 - 15:45 1280 - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression outcomes
D. Planchard¹, M. Boyer², J. Lee³, A. Dechaphunkul⁴, P. Cheema⁵, T. Takahashi⁶, A. Todd⁷, A. McKeown⁸, Y. Rukazenkov⁹, Y. Ohe¹⁰; ¹Villejuif, FR, ²Camperdown, NSW/AU, ³Seongnam, Gyeonggi-do/KR, ⁴Hat Yai, TH, ⁵Toronto, CA, ⁶Shizuoka, Shizuoka/Jp, ⁷Cambridge, GB, ⁸Melbourn, Royston, GB, ⁹Macclesfield, Cheshire/GB, ¹⁰Tokyo, JP
- 15:45 - 16:05 1290 - EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
T. Jiang, C. Zhou; Shanghai, CN

14:45 - 16:15 Less frequent driving alterations Room C

- 14:45 - 15:05 MET
A. Cortot, Lille, FR
- 15:05 - 15:25 BRAF
C. Rolfo, Edegem, BE
- 15:25 - 15:45 RET and NTRK
R. Doebele, Aurora, CO/US
- 15:45 - 16:05 HER2 and others
E. Felip Font, Barcelona, ES
- 16:05 - 16:15 Q&A



14:45 - 16:15	Multidisciplinary Tumour Board	Room A
14:45 - 15:15	Can we rely on liquid biopsy for treatment decision at the time of acquired resistance? <u>J. Remon-Masip</u> , Barcelona, ES	
15:15 - 15:45	EGFR activating mutation plus exon 20 co-mutation at baseline: Which TKI should we select for frontline treatment? <u>F. Cappuzzo</u> , Ravenna, IT	
15:45 - 16:15	Progression on osimertinib: When is it possible to continue with a targeted therapy? <u>D. Planchard</u> , Villejuif, FR	
16:15 - 16:45	Coffee break	Hall 1
16:45 - 18:15	How to prioritise the use of biomarkers	Room C
16:45 - 17:05	Clinical oncologist's perspective on biomarker testing by next generation sequencing <u>J.C. Yang</u> , Taipei, TW	
17:05 - 17:25	The value of circulating tumour DNA testing in radiotherapy <u>C. Le Pechoux</u> , Villejuif, CEDEX/FR	
17:25 - 17:45	Lung cancer biomarkers relevant to thoracic surgery practice <u>P. Van Schil</u> , Edegem, BE	
17:45 - 18:05	Pathologist's challenges in biomarker testing <u>M. Tsao</u> , Toronto, Ontario/CA	
18:05 - 18:15	Q&A	



16:45 - 18:18	5th ESO Lung Cancer Observatory Moderation: M. Aapro ¹ , E. Felip Font ² ; ¹ Genolier, CH, ² Barcelona, ES	Room W
16:45 - 16:55	Tobacco control, strategies and figures: What's next? <u>C. Adams</u> , Geneva, CH	
16:55 - 17:05	Lung cancer screening in 2019? <u>H. De Koning</u> , Rotterdam, NL	
17:05 - 17:15	Early-stage NSCLC, next steps: Staging, surgery, molecular determinations	
17:15 - 17:25	Radiation oncology: New approaches in 2019 <u>F. Mornex</u> , Pierre Bénite, CEDEX/FR	
17:25 - 17:35	What to ask your pathologist today and in 2019? <u>K. Kerr</u> , Aberdeen, GB	
17:35 - 17:45	Developments in immunotherapy: What practice changing studies will mature in 2019?	
17:45 - 17:55	Developments in targeted therapies: What practice changing studies will mature in 2019? <u>E. Felip Font</u> , Barcelona, ES	
17:55 - 18:05	The patient's perspective <u>F. Johansson</u> , Stockholm, Sweden/SE	
18:05 - 18:18	Panel discussion	
18:40 - 19:40	Industry Satellite Symposium 8	Room A
18:40 - 19:40	Industry Satellite Symposium 9	Room C
14.04.2018		
08:45 - 09:15	Keynote lecture	Room A
08:45 - 09:15	Early detection of lung cancer <u>N. Peled</u> , Petah Tikva, IL	



09:20 - 10:50	New perspectives in the treatment of SCLC	Room A
09:20 - 09:40	Chemotherapy and SCLC: The past, the present and also the future? <u>M. O'Brien</u> , London, GB	
09:40 - 10:00	Radiotherapy: What is in place today and what might the future hold? <u>U. Ricardi</u> , Torino, IT	
10:00 - 10:20	New targets in this "target orphan" disease <u>G. Riely</u> , New York, NY/US	
10:20 - 10:40	The current role of immunotherapy and its place in the future <u>L. Horn</u> , Nashville, TN/US	
10:40 - 10:50	Q&A	
10:50 - 11:20	Coffee break	Hall 1
11:20 - 12:50	Non-small cell neuro-endocrine tumours	Room A
11:20 - 11:40	Diagnosis and pathology classification <u>A.G. Nicholson</u> , London, GB	
11:40 - 12:00	Treatment of large cell neuro-endocrine carcinoma <u>A. Dingemans</u> , Maastricht, NL	
12:00 - 12:20	Staging and surgical treatment of carcinoids <u>M. García-Yuste</u> , Valladolid, ES	
12:20 - 12:40	Non-surgical treatment of carcinoids <u>A. Lamarca</u> , Manchester, GB	
12:40 - 12:50	Q&A	
12:50 - 13:00	Closing remarks	Room A